EMI Holding 10-Q 13 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 12, 2014
Document And Entity Information	'	'
Entity Registrant Name	'EMMAUS LIFE SCIENCES, INC.	'
Entity Central Index Key	'0001420031	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	27,960,487
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
CURRENT ASSETS	'	'
Cash and cash equivalents	$1,640,532	$3,638,600
Accounts receivable	53,654	35,237
Inventories, net	223,780	239,009
Marketable securities	90,768	162,564
Prepaid expenses and other current assets	144,374	81,046
Total current assets	2,153,108	4,156,456
PROPERTY AND EQUIPMENT, Net	39,224	26,120
OTHER ASSETS	'	'
Marketable securities, pledged to creditor	383,080	686,090
Intangibles, net	946,429	1,107,143
Deposits	135,860	137,900
Total other assets	1,465,369	1,931,133
Total Assets	3,657,701	6,113,709
CURRENT LIABILITIES	'	'
Accounts payable and accrued expenses	2,063,277	2,283,446
Due to related party	394,446	394,446
Dissenting stockholders payable	'	125,000
Notes payable, net	1,110,000	1,765,070
Notes payable to related parties, net	825,562	925,641
Convertible notes payable, net	3,549,221	4,802,472
Convertible notes payable to related parties	525,066	560,706
Total current liabilities	8,467,572	10,856,781
LONG-TERM LIABILITIES	'	'
Liability classified warrants	9,594,000	5,928,000
Notes payable	833,335	200,000
Notes payable to related parties	133,333	'
Convertible notes payable, net	4,387,780	2,966,588
Convertible notes payable to related parties	200,000	'
Total long-term liabilities	15,148,448	9,094,588
Total Liabilities	23,616,020	19,951,369
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Preferred stock - par value $0.001 per share, 20,000,000 shares authorized, none issued and outstanding	'	'
Common stock - par value $0.001 per share, 100,000,000 shares authorized, 30,390,103 and 29,228,306 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	30,390	29,228
Additional paid-in capital	47,772,911	35,669,291
Accumulated other comprehensive (loss) income	-117,804	262,683
Accumulated deficit	-67,643,816	-49,798,862
Total Stockholders' Deficit	-19,958,319	-13,837,660
Total Liabilities & Stockholders' Deficit	$3,657,701	$6,113,709

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Condensed Consolidated Balance Sheets Parenthetical	'	'
Preferred stock, par (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	30,390,103	29,228,306
Common stock, shares outstanding	30,390,103	29,228,306

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
REVENUES, Net	$155,644	$66,129	$347,737	$246,897
COST OF GOODS SOLD	90,421	48,445	198,203	147,418
GROSS PROFIT	65,223	17,684	149,534	99,479
OPERATING EXPENSES	'	'	'	'
Research and development	507,377	490,138	1,708,766	1,801,399
Selling	115,060	120,647	363,874	377,335
General and administrative	2,759,098	2,506,808	9,012,391	7,338,211
Transaction costs	'	1,014,019	'	1,014,019
[OperatingExpenses]	3,381,535	4,131,612	11,085,031	10,530,964
LOSS FROM OPERATIONS	-3,316,312	-4,113,928	-10,935,497	-10,431,485
OTHER INCOME (EXPENSE)	'	'	'	'
Gain on derecognition of accounts payable	'	'	'	341,361
Change in fair value of liability classified warrants	84,000	291,000	-1,895,744	291,000
Warrant exercise inducement expense	'	'	-3,523,000	'
Interest and other income	97,370	5,089	74,204	15,811
Interest expense	-591,494	-567,491	-1,562,417	-1,668,501
[NonoperatingIncomeExpense]	-410,124	-271,402	-6,906,957	-1,020,329
LOSS BEFORE INCOME TAXES	-3,726,436	-4,385,330	-17,842,454	-11,451,814
INCOME TAXES (BENEFIT)	'	-51,129	2,500	-450,381
NET LOSS	-3,726,436	-4,334,201	-17,844,954	-11,001,433
COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS)	'	'	'	'
Unrealized holding (loss) gain on securities available-for-sale	-80,593	81,261	-374,806	719,857
Unrealized foreign translation	-5,006	-7,949	-5,681	-34,381
COMPREHENSIVE LOSS	($3,812,035)	($4,260,889)	($18,225,441)	($10,315,957)
NET LOSS PER COMMON SHARE (in dollars per share)	($0.12)	($0.16)	($0.60)	($0.43)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (in shares)	30,303,396	27,066,743	29,637,402	25,694,988

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (USD $)	Common stock - par value $0.001 per share,100,000,000 shares authorized [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Dec. 31, 2013	$29,228	$35,669,291	$262,683	($49,798,862)	($13,837,660)
Balance, beginning, shares at Dec. 31, 2013	29,228,306	'	'	'	29,228,306
Beneficial conversion feature relating to convertible notes payable	'	465,926	'	'	465,926
Warrant issued in conjunction with convertible note	'	126,732	'	'	126,732
Proceeds from exercise of warrants	1,208	4,215,870	'	'	4,217,078
Proceeds from exercise of warrants, shares	1,208,379	'	'	'	'
Conversion of notes payable to common stock	454	1,497,925	'	'	1,498,379
Conversion of notes payable to common stock, shares	453,418	'	'	'	'
Excess value of liability classified warrants upon exercise	'	1,752,744	'	'	1,752,744
Common stock repurchased and cancelled	-500	-377,000	'	'	-377,500
Common stock repurchased and cancelled, shares	-500,000	'	'	'	'
Share-based compensation	'	4,421,423	'	'	4,421,423
Unrealized loss on marketable securities, net of tax	'	'	-374,806	'	-374,806
Foreign currency translation effect	'	'	-5,681	'	-5,681
Net loss	'	'	'	-17,844,954	-17,844,954
Balance, ending at Sep. 30, 2014	$30,390	$47,772,911	($117,804)	($67,643,816)	($19,958,319)
Balance, ending, shares at Sep. 30, 2014	30,390,103	'	'	'	30,390,103

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($17,844,954)	($11,001,433)
Adjustments to reconcile net loss to net cash flows from operating activities	'	'
Depreciation and amortization	172,713	177,886
Interest expense accrued from discount of convertible note	680,994	762,000
Gain on derecognition of accounts payable	'	-341,361
Share-based compensation	4,421,423	3,677,967
Warrant exercise inducement expense	3,523,000	'
Change in fair value of liability classified warrants	1,895,744	-291,000
Tax benefit recognized on unrealized gain on marketable securities available-for-sale	'	-452,931
Transaction costs related to private placement	'	1,014,019
Net changes in operating assets and liabilities	'	'
Accounts receivable	-19,241	54,672
Inventories	14,657	27,349
Prepaid expenses and other current assets	-66,992	-15,016
Deposits	-338	140,776
Accounts payable and accrued expenses	-43,559	610,466
Net cash flows used in operating activities	-7,266,553	-5,636,606
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Purchases of property and equipment	-25,775	-5,495
Net cash flows used in investing activities	-25,775	-5,495
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from notes payable issued	'	4,705,467
Proceeds from convertible notes payable issued	1,720,000	3,147,298
Due to dissenters	-125,000	-75,000
Repurchase of common stock	-377,500	'
Payments of notes payable	'	-4,298,385
Payment of convertible notes payable	-138,744	-754,480
Proceeds from private placement units, net of transaction costs	'	6,435,055
Proceeds from exercise of warrants	4,217,078	'
Proceeds from issuance of common stock	'	1,890,122
Net cash flows from financing activities	5,295,834	11,050,077
Effect of exchange rate changes on cash	-1,574	-37,615
Net (decrease) increase in cash and cash equivalents	-1,998,068	5,370,361
Cash and cash equivalents, beginning of period	3,638,600	402,823
Cash and cash equivalents, end of period	1,640,532	5,773,184
SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES	'	'
Interest paid	322,445	187,823
Income taxes paid	2,500	2,550
Non-cash financing activities:	'	'
Stock issued as a payment of professional fee	'	118,224
Conversion of notes payable to common stock	1,404,552	2,606,100
Conversion of accrued interest payable to common stock	$93,827	$20,872

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
DESCRIPTION OF BUSINESS	'
	NOTE 1 — DESCRIPTION OF BUSINESS
	Organization — Emmaus Life Sciences, Inc. (the “Company” or “Emmaus”), which is engaged in the discovery, development, and commercialization of innovative treatments and therapies primarily for rare and orphan diseases, was incorporated in the state of Delaware on September 24, 2007. Pursuant to an Agreement and Plan of Merger, dated April 21, 2011 (the “Merger Agreement”), by and among the Company, AFH Merger Sub, Inc., a wholly-owned subsidiary of the Company (“AFH Merger Sub”), AFH Holding and Advisory, LLC (“AFH Advisory”), and Emmaus Medical, Inc. (“Emmaus Medical”), Emmaus Medical merged with and into AFH Merger Sub with Emmaus Medical continuing as the surviving entity (the “Merger”). Upon the closing of the Merger, the Company changed its name from “AFH Acquisition IV, Inc.” to “Emmaus Holdings, Inc.” and became the parent company of Emmaus Medical. The Company changed its name from “Emmaus Holdings, Inc.” to “Emmaus Life Sciences, Inc.” on September 14, 2011.
	Emmaus Medical is a Delaware corporation originally incorporated on September 12, 2003. Emmaus Medical, LLC was organized on December 20, 2000. In October 2003, Emmaus Medical, LLC conducted a reorganization and merged with Emmaus Medical. As a result of the merger, Emmaus Medical acquired the exclusive patent rights for a treatment for sickle cell disease (“SCD”).
	In October 2010, the Company established Emmaus Medical Japan, Inc., a Japanese corporation (“EM Japan”) by funding 97% of the initial capital. EM Japan is engaged in the business of trading in nutritional supplements and other medical products and drugs. The results of EM Japan have been included in the consolidated financial statements of the Company since the date of formation. The aggregate formation cost was $52,500. Emmaus Medical acquired the additional 3% of the outstanding shares of EM Japan during the three months ended March 31, 2011 and is now the 100% owner of the outstanding share capital.
	In November 2011, the Company formed Emmaus Medical Europe, Ltd. (“EM Europe”), a wholly-owned subsidiary of Emmaus Medical. EM Europe’s primary focus is expanding the business of Emmaus Medical in Europe.
	Emmaus, its wholly-owned subsidiary, Emmaus Medical, and Emmaus Medical’s wholly-owned subsidiaries, Newfield Nutrition Corporation, EM Japan and EM Europe, are collectively referred to herein as the “Company.”
	Nature of Business — The Company has undertaken the business of developing and commercializing cost-effective treatments and therapies for rare diseases. The Company’s primary business purpose is to commercialize its treatment for SCD.
	To a lesser extent, the Company is also engaged in the marketing and sale of NutreStore®, which has received approval from the U.S. Food and Drug Administration (“FDA”), as a treatment for short bowel syndrome (“SBS”) in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication. The Company’s indirect wholly-owned subsidiary, Newfield Nutrition Corporation, sells L-glutamine as a nutritional supplement under the brand name AminoPure® through retail stores in multiple states and via importers and distributors in Japan, Taiwan and South Korea. The Company also owns a minority interest of less than 1% in CellSeed, Inc., a Japanese company listed on the Tokyo Stock Exchange, which is engaged in research and development of regenerative medicine products and the manufacture and sale of temperature-responsive cell culture equipment.
	The Company also has certain rights to regenerative medicine products owned by CellSeed and is involved in research focused on providing innovative solutions for tissue-engineering through the development of novel cell harvest methods and 3-dimensional living tissue replacement products for “cell sheet therapy” and regenerative medicine and the commercialization of such products.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of presentation — The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”) as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. These condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods ended September 30, 2014 and 2013.
	The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2013, and the notes thereto, which are included in the Company’s filings with the Securities and Exchange Commission (“SEC”).
	Going concern — The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. The Company had losses for the nine months ended September 30, 2014 totaling $17,844,954. In addition, the Company has a significant amount of notes payable and other obligations due within the next twelve months and is projecting that its operating losses and expected capital needs, including the expected costs relating to the commercialization of the Company’s pharmaceutical grade L-glutamine treatment for SCD, will exceed its existing cash balances and cash expected to be generated from operations for the foreseeable future. In order to meet the Company’s expected obligations, management intends to raise additional funds through equity and debt financings and partnership agreements. However, there can be no assurance that the Company will be able to complete any additional equity or debt financings or enter into partnership agreements. Therefore, due to the uncertainty of the Company’s ability to meet its current operating and capital expenses, there is substantial doubt about the Company’s ability to continue as a going concern, as the continuation and expansion of its business is dependent upon obtaining further financing, receiving FDA and other regulatory approval of its products, successful and sufficient market acceptance of its products, and finally, achieving a profitable level of operations. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
	Principles of consolidation — The condensed consolidated financial statements include the accounts of the Company (and its wholly-owned subsidiary, Emmaus Medical, and Emmaus Medical’s wholly-owned subsidiaries, Newfield Nutrition Corporation, EM Japan and EM Europe). All significant intercompany transactions have been eliminated.
	Estimates — Financial statements prepared in accordance with GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among other things, management has estimated the useful lives of equipment and other assets, along with the variables used to calculate the valuation of stock options and warrants using the Black-Scholes-Merton option valuation model.
	The warrants issued by the Company in a private placement in September 2013 were recorded as liability classified warrants. The initial value of such warrants as well as the fair value of additional warrants issued to replace the warrants exercised and the change in fair value of such warrants and replacement warrants were determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models except that the exercise price resets at certain dates in the future. Actual results could differ from those estimates.
	Inventories — Inventories as of September 30, 2014 are valued on a first-in, first-out basis at the lower of cost or market value. Work-in-process inventories consist of raw material L-glutamine for the Company’s AminoPure and NutreStore products that has not yet been packaged and labeled for sale.
	All of the raw material purchased during the nine months ended September 30, 2014 were from one vendor and during 2013 were from two vendors.
	Inventory by category	September 30, 2014			December 31, 2013
	Raw material	$	—		$	20,700
	Work-in-process	—			68,887
	Finished goods	223,780			149,422
		$	223,780		$	239,009
	Advertising cost — Advertising costs are expensed as incurred. Advertising costs for the nine months ended September 30, 2014 and 2013 were $185,465 and $161,301, respectively.
	Comprehensive (loss) income — Comprehensive (loss) income includes net loss and other comprehensive (loss) income. The items of other comprehensive (loss) income for the Company are unrealized gains and losses on marketable securities classified as available-for-sale and foreign translation adjustments relating to its subsidiaries. When the Company realizes a gain or loss on securities available-for-sale for which an unrealized gain or loss was previously recognized, a corresponding reclassification adjustment is made to remove the unrealized gain or loss from accumulated other comprehensive income and reflect the realized gain or loss in current operations.
	Marketable securities — Investment securities as of September 30, 2014 and December 31, 2013 are classified as available-for-sale. Available-for-sale securities are recorded at cost and any increases or decreases in fair market value are recorded as unrealized gain or loss, net of taxes in accumulated other comprehensive income. The Company monitors these investments for impairment and makes appropriate reductions in carrying values when necessary. CellSeed, Inc. securities are the only marketable security the Company currently carries on its books. The Company’s marketable securities consist of 48,550 shares of CellSeed stock which are part of 147,100 shares acquired in January 2009 for 100,028,000 Japanese Yen (equivalent to $1,109,819), at 680 Yen per share. CellSeed’s IPO (Tokyo Stock Exchange symbol 7776) was completed on March 16, 2010. As of September 30, 2014 and December 31, 2013, the closing price per share was 1,072 Yen and 1,840 Yen, respectively.
	In July 2013, based on an increase in market value of CellSeed shares, Mitsubishi UFJ Capital III Limited Partnership (Mitsubishi) released to the Company 34,300 shares of CellSeed stock. This was part of the 73,550 shares of CellSeed stock held by Mitsubishi as collateral to secure a $500,000 convertible note issued to Mitsubishi which is due in 2016. The note is now secured by the remaining 39,250 shares of CellSeed stock held by Mitsubishi as collateral.
	During the fourth quarter of 2013, the Company sold 25,000 of the shares released by Mitsubishi in open market transactions. As of September 30, 2014 and December 31, 2013, 9,300 shares of CellSeed stock are classified as a current asset, as they are available for sale by the Company. The remaining 39,250 shares of CellSeed stock are pledged to secure the Mitsubishi note and are classified as marketable securities, pledged to creditor.
	Fair value measurements — The Company defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company measures fair value under a framework that provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described as follows:
	Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.
	Level 2: Inputs to the valuation methodology include:
	·                  Quoted prices for similar assets or liabilities in active markets;
	·                  Quoted prices for identical or similar assets or liabilities in inactive markets;
	·                  Inputs other than quoted prices that are observable for the asset or liability; and
	·                  Inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	If the asset or liability has a specified (contractual) term, the Level 2 inputs must be observable for substantially the full term of the asset or liability.
	Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value assigned to marketable securities is determined by obtaining quoted prices on nationally recognized securities exchanges, and are classified as Level 1 investments at September 30, 2014. The fair value of the Company’s debt instruments is not materially different from their carrying values as presented. The fair value of the Company’s convertible debt instruments was determined based on Level 2 inputs. The carrying value of the debt was discounted based on allocating proceeds to other financial instruments within the arrangement as discussed in Note 6.
	The Company issued stock purchase warrants in conjunction with its September 2013 private placement and issued replacement warrants upon the exercise of certain of such warrants in June 2014 (see Note 7). Such warrants and replacement warrants are accounted for as liability classified warrants whose fair market value is determined using Level 3 inputs. These inputs include expected term and expected volatility.
	The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs during the nine months ended September 30, 2014 and the year ended December 31, 2013:
		Liability Classified warrants –
		Stock Purchase Warrants
		September 30, 2014			December 31, 2013
	Balance, beginning of period	$	5,928,000		$	—
	Fair value at issuance date	3,523,000			6,860,000
	To reduce the warrants exercised to intrinsic value	(1,770,256		)	—
	To record settlement of liability associated with warrants exercised	(1,752,744		)	—
	Change in fair value included in the statement of comprehensive loss	3,666,000			(932,000		)
	Balance, end of period	$	9,594,000		$	5,928,000
	The initial value of the liability classified warrants as of September 11, 2013 and the change in fair value of the liability classified warrants as of December 31, 2013, June 10, 2014 (the date of exercise and issuance) and September 30, 2014 were determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models except that the exercise price resets at certain dates in the future. The values as of September 11, 2013, December 31, 2013, June 10, 2014 and September 30, 2014 were calculated based on the following assumptions:
		September 30, 2014			June 10, 2014			December 31, 2013			Initial Value
	Stock price	$	5.1		$	5.1		$	3.6		$	3.6
	Risk-free interest rate	1.43		%	1.32		%	1.75		%	1.72		%
	Expected volatility (peer group)	69.5		%	68.2		%	63.2		%	72.4		%
	Expected life (in years)	3.95			4.26			4.7			5
	Expected dividend yield	—			—			—			—
	Number outstanding	3,020,501			3,020,501			3,020,501			3,020,501
	Balance, end of period	$	9,594,000		$	9,714,000		$	5,928,000		$	6,860,000
	Debt and Related Party Debt — The Company accounts for the proceeds from the issuance of convertible notes payable with detachable stock purchase warrants and embedded conversion features in accordance with FASB ASC 470-20, Debt with Conversion and Other Options. Under FASB ASC 470-20, the proceeds from the issuance of a debt instrument with detachable stock purchase warrants is allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds allocated to the warrants is accounted for as additional paid-in capital and the remaining proceeds are allocated to the debt instrument, which results in a discount to debt that is amortized and charged as interest expense over the term of the note agreement. Additionally, pursuant to FASB ASC 470-20, the intrinsic value of the embedded conversion feature of the convertible notes payable is included in the discount to debt and amortized and charged to interest expense over the term of the note agreement. The following chart shows the effective interest rates on the original loan principal amount for loans originated in the respective periods that either had a beneficial conversion interest or an attached warrant:
	Type of Loan	Term of		Stated		Original			Conv.		Beneficial			Warrants	Exercise		Warrant		Effective
		Loan		Annual		Loan			Rate		Conversion			Issued with	Price		FMV		Interest Rate
				Interest		Principal					Discount			Notes			Discount		Including
				Rate		Amount					Amount						Amount		Discounts
	2013 convertible notes payable	1~2 years		10	%	$	3,079,666		$3.30		$	396,801		50,000	—		$	116,831	19.1% ~ 61.6%
	2014 convertible notes payable	6 mo.~ 2 years		10	%	859,320			$3.05 ~ $3.30		465,926			50,000	$	3.5	$	126,732	28.0% ~ 100.4%
	Total					$	3,938,986				$	862,727		100,000			$	243,563
	Related party notes are disclosed as separate line items in the Company’s balance sheet presentation.
	Net loss per share — In accordance with FASB ASC Topic 260, Earnings per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Dilutive loss per share is computed in a manner similar to the basic loss per common share, except the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. As of September 30, 2014 and 2013, there were 13,993,997 and 13,811,989 shares of potentially dilutive securities outstanding, respectively. As the Company reported a net loss, none of the potentially dilutive securities were included in the calculation of diluted loss per share since their effect would be anti-dilutive for all periods presented.
	Recent accounting pronouncements — In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. This amendment will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. The core principle of the revenue recognition guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract(s); (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract(s); and (5) recognize revenue when (or as) the entity satisfies a performance obligation. For public companies, these amendments are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (early adoption prohibited). The standard permits the use of either the retrospective or cumulative effect transition method. Currently, the Company is assessing the impact of adoption of the amendment on its financial statements and accompanying notes.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern Sub-topic 205-40. The new guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. This ASU is effective for interim and annual periods beginning on or after December 15, 2016, and early adoption is permitted. The Company does not expect the adoption of this guidance to have a material impact on its financial position or results of operations.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	NOTE 3 — PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following at:
		September 30, 2014			December 31, 2013
	Equipment	$	137,038		$	128,343
	Leasehold improvements	31,304			23,054
	Furniture and fixtures	60,194			52,269
	Sub total	228,536			203,666
	Less: accumulated depreciation	(189,312		)	(177,546		)
	Total	$	39,224		$	26,120
	During the nine months ended September 30, 2014 and 2013, depreciation expense was $11,999 and $17,172, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS	'
	NOTE 4 — INTANGIBLE ASSETS
	The Company is licensed to market and sell NutreStore L-glutamine powder for oral solution as a treatment for SBS.
	In April 2011, the Company entered into a Research Agreement and an Individual Agreement with CellSeed and, in August 2011, entered into an addendum to the Research Agreement. Pursuant to the Individual Agreement, CellSeed granted the Company the exclusive right to manufacture, sell, market and distribute Cultured Autologous Oral Mucosal Epithelial Cell Sheet (“CAOMECS”) for the cornea in the United States and agreed to disclose to the Company its accumulated information package for the joint development of CAOMECS. Under the Individual Agreement, the Company agreed to pay CellSeed $1.5 million, which it paid in February 2012. The technology acquired under the Individual Agreement is being used to support an ongoing research and development project, and management believes the technology has alternative future uses in other future development initiatives.
	Pursuant to the Research Agreement, the Company and CellSeed formed a relationship regarding the future research and development of cell sheet engineering regenerative medicine products and the future commercialization of such products. Under the Research Agreement, as supplemented by the addendum, the Company agreed to pay CellSeed $8.5 million within 30 days after the completion of all of the following: (i) the execution of the Research Agreement; (ii) the execution of the Individual Agreement; and (iii) CellSeed’s delivery of the accumulated information package, as defined in the Research Agreement, to the Company and the Company providing written confirmation of its acceptance of the complete Package, which has not yet been completed as of September 30, 2014.
	The Company has estimated the economic life of the CAOMECS produced in connection with the CellSeed Research and Individual Agreement at seven years. The determination of this life is based in part on the Company’s estimate of economic useful life and the time period in which the Company may enjoy an advantage over competing technologies and techniques. Key reasons for a useful life shorter than the life of a patent include: (i) the patents related to this technology are yet to be approved, (ii) potential redundancy with similar medication/device due to changes in market preferences, (iii) uncertainty of regulatory approval, and (iv) potential development of new treatments for the same disease.
	Intangible assets consisted of the following at:
		September 30, 2014			December 31, 2013
	License fees and patent filing costs	$	2,250,000		$	2,250,000
	Less: accumulated amortization	(1,303,571		)	(1,142,857		)
	Total	$	946,429		$	1,107,143
	During the nine months ended September 30, 2014 and 2013, amortization expense was $160,714 in each period. As of September 30, 2014, aggregate amortization expense for the next five years is estimated to be as follows:
	Periods ending December 31,	Amount
	2014 (fourth quarter)	$	53,572
	2015	214,286
	2016	214,286
	2017	214,286
	2018	214,286
	Thereafter	35,713
	Total	$	946,429

ACCOUNTS_PAYABLE_AND_ACCRUED_E

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	'
	NOTE 5 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accounts payable and accrued expenses consisted of the following at:
		September 30, 2014		December 31, 2013
	Accounts payable
	Clinical trial management expenses	$	—	$	270,694
	Legal expenses	113,457		178,119
	Other vendors	541,388		386,847
	Subtotal	654,845		835,660
	Accrued interest payable, related parties	99,518		195,051
	Accrued interest payable	837,172		473,356
	Accrued expenses	180,075		294,379
	Deferred salary	291,667		485,000
	Total accounts payable and accrued expenses	$	2,063,277	$	2,283,446

NOTES_PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
NOTES PAYABLE	'
	NOTE 6 — NOTES PAYABLE
	Notes payable consisted of the following at September 30, 2014:
	Year	Interest		Term of Notes	Conv. Price	Principal		Discount		Carrying		Shares	Principal		Discount		Carrying		Shares
	Issued	rate				Outstanding		Amount		Amount		Underlying	Outstanding		Amount		Amount		Underlying
		range				September		September		September		Principal	December		December		December		Principal
						30, 2014		30, 2014		30, 2014		as of	31, 2013		31, 2013		31, 2013		as of
												September							December
												30, 2014							31, 2013
	Convertible notes payable
	2009	6.50%		5 years	$3.05	$	—	$	—	$	—	—	$	254,460	$	—	$	254,460	83,366
	2010	0 ~ 6.0%		5 years	$3.05	74,000		4,473		69,527		24,248	74,000		8,308		65,692		24,248
	2011	10%		5 years	$3.05	500,000		—		500,000		163,809	500,000		—		500,000		163,809
	2012	10%		2 years	$3.30 ~$3.60	201,600		—		201,600		56,000	251,100		—		251,100		71,000
	2013	10%		6 months ~ 2 years	$3.30 ~$3.60	4,599,445		32,687		4,566,758		1,307,922	6,913,606		215,798		6,697,808		1,998,215
	2014	10%		Due on demand ~ 2 years	$3.05 ~$7.00	2,720,412		121,296		2,599,116		578,832	—		—		—		—
						$	8,095,457	$	158,456	$	7,937,001	2,130,811	$	7,993,166	$	224,106	$	7,769,060	2,340,638
				Current		$	3,678,504	$	129,283	$	3,549,221	1,070,975	$	4,955,868	$	153,396	$	4,802,472	1,438,033
				Non-current		$	4,416,953	$	29,173	$	4,387,780	1,059,836	$	3,037,298	$	70,710	$	2,966,588	902,605
	Convertible notes payable - related party
	2012	10%		Due on demand	$3.30	$	373,000	$	—	$	373,000	113,030	$	373,000	$	—	$	373,000	113,030
	2013	10%		1 year	$3.60	152,066		—		152,066		42,241	187,706		—		187,706		52,141
	2014	10%		2 years	$7.00	200,000		—		200,000		28,571	—		—		—		—
						$	725,066	$	—	$	725,066	183,842	$	560,706	$	—	$	560,706	165,171
				Current		$	525,066	$	—	$	525,066	155,271	$	560,706	$	—	$	560,706	165,171
				Non-current		$	200,000	$	—	$	200,000	28,571	$	—	$	—	$	—	—
	Notes payable
	2012	11%		2 years	NA	$	—	$	—	$	—	—	$	833,335	$	18,265	$	815,070	—
	2013	2% ~ 10%		Due on demand ~ 2 years	NA	1,110,000		—		1,110,000		—	1,150,000		—		1,150,000		—
	2014	11%		2 years	NA	833,335		—		833,335		—	—		—		—		—
						$	1,943,335	$	—	$	1,943,335	—	$	1,983,335	$	18,265	$	1,965,070	—
				Current		$	1,110,000	$	—	$	1,110,000	—	$	1,783,335	$	18,265	$	1,765,070	—
				Non-current		$	833,335	$	—	$	833,335	—	$	200,000	$	—	$	200,000	—
	Notes payable - related party
	2012	8% ~ 10%		Due on demand	NA	$	656,730	$	—	$	656,730	—	$	880,062	$	4,421	$	875,641	—
	2013	8%		Due on demand	NA	50,000		—		50,000		—	50,000		—		50,000		—
	2014	11%		Due on demand ~ 2 years	NA	252,165		—		252,165		—	—		—		—		—
						$	958,895	$	—	$	958,895	—	$	930,062	$	4,421	$	925,641	—
				Current		$	825,562	$	—	$	825,562	—	$	930,062	$	4,421	$	925,641	—
				Non-current		$	133,333	$	—	$	133,333	—	$	—	$	—	$	—	—
				Grand Total		$	11,722,753	$	158,456	$	11,564,297	2,314,653	$	11,467,269	$	246,792	$	11,220,477	2,505,809
	The average stated interest rate of notes payable as of September 30, 2014 and December 31, 2013 was 10%. The average effective interest rate of notes payable as of September 30, 2014 and December 31, 2013 was 16% and 15%, respectively, after giving effect to discounts relating to beneficial conversion features and the fair value of warrants issued in connection with these notes. The notes payable and convertible notes payable do not have restrictive financial covenants or acceleration clauses associated with a material adverse change event. The holders of the convertible notes have the option to convert their notes into the Company’s common stock at the stated conversion price at any time during the term of their convertible notes. Conversion prices on the convertible notes payable range from $3.05 to $7.00 per share. All due on demand notes are treated as current liabilities.
	Contractual principal payments due on notes payable are as follows at September 30, 2014:
	In calendar year	Payments Due
	2014 (fourth quarter)	$	3,391,977
	2015	2,749,155
	2016	5,581,621
	Total	$	11,722,753
	The Company estimated the total fair value of any beneficial conversion feature and accompanying warrants in allocating the debt proceeds. The proceeds allocated to the beneficial conversion feature were determined by taking the estimated fair value of shares issuable under the convertible notes less the fair value of the number of shares that would be issued if the conversion rate equaled the fair value of the Company’s common stock as of the date of issuance (see Note 2). In situations where the debt included both a beneficial conversion feature and a warrant, the proceeds were allocated to the warrants and beneficial conversion feature based on the pro-rata fair value.

STOCKHOLDERS_EQUITY_DEFICIT

STOCKHOLDERS' EQUITY (DEFICIT)	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY (DEFICIT)	'
	NOTE 7 — STOCKHOLDERS’ DEFICIT
	Private Placement — On September 11, 2013, the Company issued an aggregate of 3,020,501 units at a price of $2.50 per unit (the “Private Placement”). Each unit consisted of one share of common stock and one common stock warrant for the purchase of an additional share of common stock. The aggregate purchase price for the units was $7,551,253.
	The warrants entitle the holders thereof to purchase, at any time on or prior to September 11, 2018, shares of common stock of the Company at an exercise price of $3.50 per share. The warrants contain non-standard anti-dilution protection and, consequently, are being accounted for as liability classified warrants, were originally recorded at fair value, and will be adjusted to fair market value each reporting period.
	Stock warrants — In addition to the warrants issued in connection with the Private Placement discussed above, during the year ended December 31, 2013, the Company issued warrants in connection with the issuance of a convertible note to purchase an aggregate of 50,000 shares of common stock at a per share exercise price of $3.30 per share. Also, in December 2013, warrants to purchase 500,000 shares of common stock at an exercise price of $1.00 per share that had previously been issued to a director expired. On May 1, 2014, in connection with the issuance of a convertible note, the Company issued a five year warrant to purchase an aggregate of 50,000 shares of common stock at an exercise price of $3.50 per share.
	Warrant exercises and issuance — On June 10, 2014, certain warrant holders exercised 1,095,465 warrants issued in the Private Placement for the exercise price of $3.50 per share, resulting in the Company receiving aggregate exercise proceeds of $3.8 million and issuing 1,095,465 shares of common stock. Prior to exercise, these Private Placement warrants were accounted for at fair value as liability classified warrants. As of June 10, 2014, immediately prior to exercise, the carrying value of these Private Placement warrants was reduced to their fair value immediately prior to exercise of $1.8 million, representing their intrinsic value, with this adjusted carrying value of $1.8 million being transferred to additional paid in capital. Also on June 10, 2014, based on an offer made to holders of Private Placement warrants in connection with such exercises, the Company issued an aggregate of 1,095,465 replacement warrants to holders exercising Private Placement warrants, which replacement warrants have terms that are generally the same as the exercised warrants, including an expiration date of September 11, 2018 and an exercise price of $3.50 per share. The replacement warrants are treated for accounting purposes as liability classified warrants, and their issuance gave rise to a $3.5 million warrant exercise inducement expense based on their fair value as of issuance as determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model.
	In addition to the above, during the nine months ended September 30, 2014, the Company issued 112,914 shares of common stock upon the exercise of warrants at exercise prices ranging from $3.05 to $3.825 per share, including 5,246 warrants exercised on a cashless basis.
	A summary of outstanding warrants as of September 30, 2014 is presented below.
		Nine months ended		Year ended
		September 30, 2014		December 31, 2013
	Warrants outstanding, beginning of period	6,279,296		3,408,795
	Granted	1,145,465		3,370,501
	Exercised	(1,208,379	)	—
	Cancelled, forfeited and expired	(419,153	)	(500,000	)
	Warrants outstanding, end of period	5,797,229		6,279,296
	A summary of outstanding warrants by year issued and exercise price as of September 30, 2014 is presented below.
		Outstanding							Exercisable
	Year issued and	Number of		Weighted		Weighted			Total		Weighted
	Exercise Price	Warrants Issued		Average		Average					Average
				Remaining		Exercise Price					Exercise
				Contractual							Price
				Life (Years)
	Balance 2012
	$1.00	946,576		0.29		$	1		946,576		$	1
	$2.50	1,000,000		0.91		$	2.5		1,000,000		$	2.5
	$3.05	241,495		0.77		$	3.05		241,495		$	3.05
	75% of FMV	188,657		0.1		75% of FMV			188,657		75% of FMV
	2012 total	2,376,728							2,376,728
	During 2013
	$3.30	50,000		3.59		$	3.3		50,000		$	3.3
	$3.50	2,225,036		3.95		$	3.5		2,225,036		$	3.5
	2013 total	2,275,036							2,275,036
	During 2014
	$3.50	1,145,465		3.98		$	3.5		1,145,465		$	3.5
	Total	5,797,229							5,797,229
	Stock options — Management has valued stock options at their date of grant utilizing the Black-Scholes-Merton Option pricing model. The fair value of the underlying shares was determined by the market value of stock of similar companies and recent arm’s length transactions involving the sale of common stock. The expected volatility was calculated using the historical volatility of a similar public entity in the industry through August 2013 and a group of similar public entities thereafter. The following table shows assumptions used on recent dates on which options were granted by the Board of Directors.
		July 17, 2014			May 8, 2014			February 26, 2014			July 18, 2013			February 28, 2013
	Stock price	$	5.1		$	4.9		$	3.6		$	3.6		$	3.6
	Exercise price	$	5.1		$	4.9		$	3.6		$	3.6		$	3.6
	Term	10 years			10 years			10 years			10 years			10 years
	Risk-Free Interest Rate	2.47		%	2.61		%	2.67		%	2.56		%	1.89		%
	Dividend Yield	0		%	0		%	0		%	0		%	0		%
	Volatility	77.9		%	75.5		%	76.6		%	113.6		%	119.3		%
	In making the determination of fair value and finding similar companies, the Company considered the industry, stage of life cycle, size and financial leverage of such other entities. While the Company was initially able to identify only one similar public company using these criteria, based on the more advanced stage of development of the Company additional similar companies with enough historical data that met the industry criterion have now been identified. Accordingly, the Company has based its expected volatility on the historical stock prices of a group of companies since September 2013.
	The risk-free interest rate is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options depending on the date of the grant and expected life of the options. The expected life of options used was based on the contractual life of the option granted.
	During the nine months ended September 30, 2014, the Company’s Board of Directors granted 840,000 options to its directors, employees and consultants. Of these options, 438,000 options will vest over three years starting February 26, 2015, have an exercise price of $3.60 per share, and are exercisable through 2024, 302,000 options will vest over three years starting May 8, 2015, have an exercise price of $4.90 per share, and are exercisable through 2024, and 100,000 options will vest over three years starting July 17, 2015, have an exercise price of $5.10 per share, and are exercisable through 2024. In addition, 340,000 options that were approved by the Company’s Board of Directors in April 2012 were deemed issued during the nine months ended September 30, 2014. Two-thirds of these options have vested and the remaining one-third will vest by April 2015. These options have an exercise price of $3.60 per share and are exercisable through 2022. The aggregate fair value of these groups of options was approximately $2.7 million. As of September 30, 2014, there were 5,669,000 options outstanding under the 2011 Stock Incentive Plan and 11,795 options outstanding that were issued prior to the 2011 Stock Incentive Plan.
	A summary of outstanding options as of September 30, 2014 is presented below.
				2011 Stock Incentive Plan
		Prior Plan		September 30, 2014		December 31, 2013
	Options outstanding, beginning of period	11,795		4,504,000		1,199,000
	Granted	—		1,180,000		3,305,000
	Exercised	—		—		—
	Cancelled, forfeited and expired	—		(15,000	)	—
	Options outstanding, end of period	11,795		5,669,000		4,504,000
	Registration Rights — Pursuant to the Subscription Agreements and certain warrants, the Company has agreed to use its commercially reasonable best efforts to have on file with the SEC, by September 11, 2014 and at the Company’s sole expense, a registration statement to permit the public resale of 4,115,966 shares of the Company’s common stock and 3,320,501 shares of common stock underlying warrants (collectively, the “Registrable Securities”). In the event such registration statement includes securities to be offered and sold by the Company in a fully underwritten primary public offering pursuant to an effective registration under the Securities Act, and the Company is advised in good faith by any managing underwriter of securities being offered pursuant to such registration statement that the number of Registrable Securities proposed to be sold in such offering is greater than the number of such securities which can be included in such offering without materially adversely affecting such offering, the Company will include in such registration the following securities in the following order of priority: (i) any securities the Company proposes to sell; and (ii) the Registrable Securities, with any reductions in the number of Registrable Securities actually included in such registration to be allocated on a pro rata basis among the holders thereof. The registration rights described above apply until all Registrable Securities have been sold pursuant to Rule 144 under the Securities Act or may be sold without registration in reliance on Rule 144 under the Securities Act without limitation as to volume and without the requirement of any notice filing. If the shares of common stock underlying warrants to purchase 2,225,036 shares are not registered for resale at the time of exercise on or after September 11, 2014 or if the shares of common stock underlying warrants to purchase 1,095,465 shares are not registered for resale at the time of exercise on or after June 10, 2015, and in each such case the registration rights described above then apply with respect to the holder of such warrants, such holder may exercise such warrants on a cashless basis. The Company has not yet filed a registration statement with respect to the resale of the Registrable Securities because doing so is not feasible prior to the completion by the Company of its initial public offering.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 8 — COMMITMENTS AND CONTINGENCIES
	Distribution contract — Cardinal Health Specialty Pharmacy Services has been contracted to distribute NutreStore to other wholesale distributors and some independent pharmacies since April 2008. For these services, the Company pays a monthly commercialization management fee of $5,000.
	Operating leases — The Company leases its office space under operating leases with unrelated entities. The rent expense during the nine months ended September 30, 2014 and 2013 amounted to $163,605 and $101,891, respectively.
	Future minimum lease payments under the agreements are as follows:
	2014	$	50,304
	2015	122,434
	2016	41,067
		$	213,805
	Licensing agreement — The Company licensed certain current and future technology from CellSeed (see Note 4 for further discussion). CellSeed may terminate these agreements with the Company if the Company is unable to make timely payments required under the agreements. At the time the Company entered into the agreements with CellSeed, it left for further negotiation provisions covering how the Company and CellSeed will share any financial results of commercializing any cell sheet engineering regenerative medicine products that it is seeking to develop in collaboration with CellSeed. If the Company is not able to successfully negotiate these terms, its current development and commercialization plans with respect to any of these products would be materially adversely affected.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE 9 — RELATED PARTY TRANSACTIONS
	The following table sets forth information relating to the Company’s loans from related persons outstanding as of September 30, 2014.
	Class	Lender	Interest		Date of	Term of Loan	Principal			Highest		Amount of					Amount of					Conv.		Shares
			rate		loan		Amount			Principal		Principal					Interest					Rate		underlying
							Outstanding			outstanding		Repaid					Paid							principal
							at																	at
							September 30,																	September 30,
							2014																	2014
	Current, Promissory note payable to related parties:
		Hope Int’l Hospice (1)	8	%	1/17/12	Due on demand	$	200,000		$	200,000	$	—				$		12,000			—		—
		Hope Int’l Hospice (1)	8	%	6/14/12	Due on demand	200,000			200,000		—					16,000					—		—
		Hope Int’l Hospice (1)	8	%	6/21/12	Due on demand	100,000			100,000		—					6,000					—		—
		Yutaka Niihara (2)(4)	10	%	12/5/12	Due on demand	156,730			1,213,700		1,056,970					60,851					—		—
		Hope Int’l Hospice (1)	8	%	2/11/13	Due on demand	50,000			50,000		—					3,000					—		—
		Lan T. Tran (2)	11	%	2/10/14	2 years (3)	106,976			106,976		—					—					—		—
		Cuc T. Tran (5)	11	%	3/5/14	1 year	11,856			11,856		—					—					—		—
						Sub total	$	825,562		$	1,882,532	$		1,056,970			$			97,851		—		—
	Current, Convertible notes payable to related parties:
		Yasushi Nagasaki (2)	10	%	6/29/12	Due on demand	$	373,000		$	388,800	$	15,800				$		67,680			$	3.3	113,030
		MLPF&S Cust. FBO Willis C.Lee (2)	10	%	10/5/13	1 year	152,066			152,066		—					—					$	3.6	42,241
						Sub total	$	525,066		$	540,866	$			15,800		$		67,680			—		155,271
	Long-term, Promissory note payable to related parties:
		Hideki & Eiko Uehara (5)	11	%	2/15/14	2 years	$	133,333		$	133,333	$	—				$		11,030			—		—
						Sub total	$	133,333		$	133,333	$	—				$	11,030				—		—
	Long-term, Convertible notes payable to related parties:
		Phillip M. Satow (4)	10	%	6/6/14	2 years	$	100,000		$	100,000	$	—				$		—			$	7	14,286
		Richard S. Pechter (5)	10	%	6/11/14	2 years	100,000			100,000		—					—					$	7	14,286
						Sub total	$	200,000		$	200,000	$	—				$		—			—		28,572
						Total	$	1,683,961		$	2,756,731	$	1,072,770				$		176,561			—		183,843
	(1)    Dr. Niihara is also the CEO of Hope International Hospice, Inc.
	(2)    Officer
	(3)    Due on demand
	(4)    Director
	(5)    Family of Officer/Director
	The following table sets forth information relating to the Company’s loans from related persons outstanding as of December 31, 2013.
	Class	Lender	Interest		Date of	Term of Loan	Principal			Highest		Amount of			Amount of			Conv.			Shares
			rate		loan		Amount			Principal		Principal			Interest			Rate			Underlying
							Outstanding			outstanding		Repaid			Paid						Principal
							as  of														as of
							December 31,														December
							2013														31, 2013
	Current, Promissory note payable to related parties:
		Hope Int’l Hospice(1)	8	%	1/17/12	Due on demand	$	200,000		$	200,000	$	—		$	20,000		—			—
		Lan T. Tran(2)	11	%	2/10/12	2 years(3)	80,000			205,000		125,000			—			—			—
		Hideki & Eiko Uehara(5)	11	%	2/15/12	2 years(3)	133,333			133,333		—			14,433			—			—
		Hope Int’l Hospice(1)	8	%	6/14/12	Due on demand	200,000			200,000		—			20,000			—			—
		Hope Int’l Hospice(1)	8	%	6/21/12	Due on demand	100,000			100,000		—			10,000			—			—
		Cuc T. Tran(5)	11	%	6/27/12	1 year	10,000			10,000		—			—			—			—
		Yutaka Niihara(2)(4)	10	%	12/5/12	Due on demand	156,730			1,213,700		1,056,970			—			—			—
		Hope Int’l Hospice(1)	8	%	2/11/13	Due on demand	50,000			50,000		—			3,000			—			—
						Sub total	$	930,063		$	2,112,033	$	1,181,970		$	67,433		—			—
						Less discount	$	(4,422	)
						Total	$	925,641
	Current, Convertible notes payable to related parties:
		Yasushi Nagasaki(2)	10	%	6/29/12	Due on demand	$	373,000		$	388,800	$	15,800		$	—		$	3.3		113,030
		Hideki & Eiko Uehara(5)	10	%	9/7/13	1 year	35,640			35,640		—			—			$	3.6		9,900
		MLPF&S Cust. FBO Willis C.Lee(2)(4)	10	%	10/5/13	1 year	152,066			152,066		—			—			$	3.6		42,240
						Sub total	$	560,706		$	576,506	$	15,800		$	—		—			165,170
						Total	$	1,486,347		$	2,688,539	$	1,197,770		$	67,433		—			165,170
	(1)    Dr. Niihara, who is the Company’s CEO, is also the CEO of Hope International Hospice, Inc.
	(2)    Officer
	(3)    Due on demand
	(4)    Director
(5)    Family of Officer/Director
Since July 2012, the Company has been engaged in litigation with AFH Advisory, which was the sole stockholder of AFH Acquisition IV immediately prior to its combination with Emmaus Medical pursuant to the Merger in May 2011. In September 2012, AFH Advisory and related parties filed a complaint against the Company in the Superior Court of Delaware. In October 2012, the Company filed counterclaims against the plaintiffs and third-party claims against Amir Heshmatpour. Mr. Heshmatpour is a former officer of AFH Acquisition IV, Inc. (prior to the Merger) and former director of the Company and is the Managing Partner of AFH Advisory. On June 27, 2013, the Superior Court of the State of Delaware issued an order implementing a partial summary judgment in favor of the Company in its litigation against AFH Advisory, Griffin, the Foundation and Mr. Heshmatpour. The order, among other things, (i) stated that a letter of intent previously entered into between the Company and AFH Advisory (the “Letter of Intent”) was properly terminated as of July 19, 2012 by the Company, and (ii) ordered the transfer agent for the Company to effect the cancellation of 2,504,249 shares of the Company’s common stock held by AFH Advisory, Griffin and the Foundation. The cancellation of such shares was effected by the Company’s transfer agent on June 28, 2013. While no appeal of this ruling has been pursued, if the court’s ruling is appealed, it could result in the Company incurring liabilities and expenses that may have a material adverse effect on its financial condition and cash flows. The cancellation of such shares is subject to appeal until 30 days after the completion of trial court proceedings. While the partial summary judgment in favor of the Company in this litigation noted above led to the cancellation of 2,504,249 shares of the Company’s common stock by the transfer agent on June 28, 2013, the Company will continue to present these shares in its financial statements as outstanding until the right of appeal has lapsed and all contingencies have been resolved. The Company’s cause of action for fraud, which was not part of the summary judgment, has not yet been litigated or settled.

GEOGRAPHIC_INFORMATION

GEOGRAPHIC INFORMATION	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
GEOGRAPHIC INFORMATION	'
	NOTE 10 — GEOGRAPHIC INFORMATION
	For the nine months ended September 30, 2014 and 2013, the Company earned revenue from countries outside of the United States as outlined in the table below. The Company did not have any significant currency translation or foreign transaction adjustments during the nine months ended September 30, 2014 or 2013.
	Country	Sales nine months ended		% of Total revenue		Sales nine months ended		% of Total revenue
		September 30, 2014		nine months ended		September 30, 2013		nine months ended
				September 30, 2014				September 30, 2013
	Japan	$	132,145	38	%	$	125,590	51	%
	South Korea	45,312		13	%	—		—
	Taiwan	129,310		37	%	7,980		3	%

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 11 — SUBSEQUENT EVENTS
	In October 2014, $131,717 in principal amount of a convertible note was converted into common stock at a conversion price of $3.60 per share.
	In October 2014, warrants to purchase 35,556 shares of the Company’s common stock were exercised at an exercise price of $1.00 per share.
	In October 2014, the Company refinanced its principal obligation under a convertible note payable in the amount of $2,136,146 by issuing a new convertible note in the same principal amount and having the same interest rate, same conversion terms and a two year maturity. In addition, a new promissory note bearing interest at 11% was issued to this same lender to evidence $213,615 of accrued interest on the initial note and $400,000 of additional loan proceeds. A summary of these notes is as follows:
	Notes issued after	Loan Principal		Annual		Term of Notes	Conversion		Date of loan
	September 30, 2014	Outstanding		Interest Rate			Price
	Convertible note	$	2,136,146	10	%	2 years	$	3.6	10/10/14
	Promissory note	613,615		11	%	On demand up to 2 years	—		10/10/14
		$	2,749,761
	In October 2014, the Company entered into a fifty-one-and-a-half month office lease agreement. The lease term commences on November 14, 2014 and expires on February 28, 2019. The lease agreement provides for the lease by the Company of approximately 13,329 square feet of space at 21250 Hawthorne Boulevard in Torrance, California. Base rent is set at $36,370 per month and the total rent payable over the lease term is $1,873,075.

AMOUNTS_RECLASSIFIED_OUT_OF_AC

AMOUNTS RECLASSIFIED OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME	9 Months Ended
	Sep. 30, 2014
Amounts Reclassified Out Of Accumulated Other Comprehensive Income	'
AMOUNTS RECLASSIFIED OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME	'
	NOTE 12 — AMOUNTS RECLASSIFIED OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME
	The following tables show amounts added to and reclassified out of accumulated other comprehensive income:
		Unrealized holding			Unrealized			Total
		gain (loss) on			foreign
		securities			translation
		available-for-sale
	Balance — December 31, 2013	$	289,389		$	(26,706	)	$	262,683
	Other comprehensive income before reclassifications	(374,806		)	(5,681		)	(380,487		)
	Amounts reclassified from accumulated other comprehensive income	—			—			—
	Net current period other comprehensive income	(374,806		)	(5,681		)	(380,487		)
	Balance — September 30, 2014	$	(85,417	)	$	(32,387	)	$	(117,804	)
	Balance — December 31, 2012	$	(4,386	)	$	(8,046	)	$	(12,432	)
	Other comprehensive income before reclassifications	719,857			(34,381		)	685,476
	Amounts reclassified from accumulated other comprehensive income	—			—			—
	Net current period other comprehensive income	719,857			(34,381		)	685,476
	Balance — September 30, 2013	$	715,471		$	(42,427	)	$	673,044
	Amounts in parentheses indicate debits.
	All amounts are net of tax.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of presentation	'
	Basis of presentation — The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”) as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. These condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods ended September 30, 2014 and 2013.
	The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2013, and the notes thereto, which are included in the Company’s filings with the Securities and Exchange Commission (“SEC”).
Going concern	'
	Going concern — The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. The Company had losses for the nine months ended September 30, 2014 totaling $17,844,954. In addition, the Company has a significant amount of notes payable and other obligations due within the next twelve months and is projecting that its operating losses and expected capital needs, including the expected costs relating to the commercialization of the Company’s pharmaceutical grade L-glutamine treatment for SCD, will exceed its existing cash balances and cash expected to be generated from operations for the foreseeable future. In order to meet the Company’s expected obligations, management intends to raise additional funds through equity and debt financings and partnership agreements. However, there can be no assurance that the Company will be able to complete any additional equity or debt financings or enter into partnership agreements. Therefore, due to the uncertainty of the Company’s ability to meet its current operating and capital expenses, there is substantial doubt about the Company’s ability to continue as a going concern, as the continuation and expansion of its business is dependent upon obtaining further financing, receiving FDA and other regulatory approval of its products, successful and sufficient market acceptance of its products, and finally, achieving a profitable level of operations. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
Principles of consolidation	'
	Principles of consolidation — The condensed consolidated financial statements include the accounts of the Company (and its wholly-owned subsidiary, Emmaus Medical, and Emmaus Medical’s wholly-owned subsidiaries, Newfield Nutrition Corporation, EM Japan and EM Europe). All significant intercompany transactions have been eliminated.
Estimates	'
	Estimates — Financial statements prepared in accordance with GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among other things, management has estimated the useful lives of equipment and other assets, along with the variables used to calculate the valuation of stock options and warrants using the Black-Scholes-Merton option valuation model.
	The warrants issued by the Company in a private placement in September 2013 were recorded as liability classified warrants. The initial value of such warrants as well as the fair value of additional warrants issued to replace the warrants exercised and the change in fair value of such warrants and replacement warrants were determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models except that the exercise price resets at certain dates in the future. Actual results could differ from those estimates.
Inventories	'
	Inventories — Inventories as of September 30, 2014 are valued on a first-in, first-out basis at the lower of cost or market value. Work-in-process inventories consist of raw material L-glutamine for the Company’s AminoPure and NutreStore products that has not yet been packaged and labeled for sale.
	All of the raw material purchased during the nine months ended September 30, 2014 were from one vendor and during 2013 were from two vendors.
	Inventory by category	September 30, 2014			December 31, 2013
	Raw material	$	—		$	20,700
	Work-in-process	—			68,887
	Finished goods	223,780			149,422
		$	223,780		$	239,009
Advertising cost	'
	Advertising cost — Advertising costs are expensed as incurred. Advertising costs for the nine months ended September 30, 2014 and 2013 were $185,465 and $161,301, respectively.
Comprehensive (loss) income	'
	Comprehensive (loss) income — Comprehensive (loss) income includes net loss and other comprehensive (loss) income. The items of other comprehensive (loss) income for the Company are unrealized gains and losses on marketable securities classified as available-for-sale and foreign translation adjustments relating to its subsidiaries. When the Company realizes a gain or loss on securities available-for-sale for which an unrealized gain or loss was previously recognized, a corresponding reclassification adjustment is made to remove the unrealized gain or loss from accumulated other comprehensive income and reflect the realized gain or loss in current operations.
Marketable securities	'
	Marketable securities — Investment securities as of September 30, 2014 and December 31, 2013 are classified as available-for-sale. Available-for-sale securities are recorded at cost and any increases or decreases in fair market value are recorded as unrealized gain or loss, net of taxes in accumulated other comprehensive income. The Company monitors these investments for impairment and makes appropriate reductions in carrying values when necessary. CellSeed, Inc. securities are the only marketable security the Company currently carries on its books. The Company’s marketable securities consist of 48,550 shares of CellSeed stock which are part of 147,100 shares acquired in January 2009 for 100,028,000 Japanese Yen (equivalent to $1,109,819), at 680 Yen per share. CellSeed’s IPO (Tokyo Stock Exchange symbol 7776) was completed on March 16, 2010. As of September 30, 2014 and December 31, 2013, the closing price per share was 1,072 Yen and 1,840 Yen, respectively.
	In July 2013, based on an increase in market value of CellSeed shares, Mitsubishi UFJ Capital III Limited Partnership (Mitsubishi) released to the Company 34,300 shares of CellSeed stock. This was part of the 73,550 shares of CellSeed stock held by Mitsubishi as collateral to secure a $500,000 convertible note issued to Mitsubishi which is due in 2016. The note is now secured by the remaining 39,250 shares of CellSeed stock held by Mitsubishi as collateral.
	During the fourth quarter of 2013, the Company sold 25,000 of the shares released by Mitsubishi in open market transactions. As of September 30, 2014 and December 31, 2013, 9,300 shares of CellSeed stock are classified as a current asset, as they are available for sale by the Company. The remaining 39,250 shares of CellSeed stock are pledged to secure the Mitsubishi note and are classified as marketable securities, pledged to creditor.
Fair value measurements	'
	Fair value measurements — The Company defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company measures fair value under a framework that provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described as follows:
	Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.
	Level 2: Inputs to the valuation methodology include:
	·                  Quoted prices for similar assets or liabilities in active markets;
	·                  Quoted prices for identical or similar assets or liabilities in inactive markets;
	·                  Inputs other than quoted prices that are observable for the asset or liability; and
	·                  Inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	If the asset or liability has a specified (contractual) term, the Level 2 inputs must be observable for substantially the full term of the asset or liability.
	Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value assigned to marketable securities is determined by obtaining quoted prices on nationally recognized securities exchanges, and are classified as Level 1 investments at September 30, 2014. The fair value of the Company’s debt instruments is not materially different from their carrying values as presented. The fair value of the Company’s convertible debt instruments was determined based on Level 2 inputs. The carrying value of the debt was discounted based on allocating proceeds to other financial instruments within the arrangement as discussed in Note 6.
	The Company issued stock purchase warrants in conjunction with its September 2013 private placement and issued replacement warrants upon the exercise of certain of such warrants in June 2014 (see Note 7). Such warrants and replacement warrants are accounted for as liability classified warrants whose fair market value is determined using Level 3 inputs. These inputs include expected term and expected volatility.
	The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs during the nine months ended September 30, 2014 and the year ended December 31, 2013:
		Liability Classified warrants –
		Stock Purchase Warrants
		September 30, 2014			December 31, 2013
	Balance, beginning of period	$	5,928,000		$	—
	Fair value at issuance date	3,523,000			6,860,000
	To reduce the warrants exercised to intrinsic value	(1,770,256		)	—
	To record settlement of liability associated with warrants exercised	(1,752,744		)	—
	Change in fair value included in the statement of comprehensive loss	3,666,000			(932,000		)
	Balance, end of period	$	9,594,000		$	5,928,000
	The initial value of the liability classified warrants as of September 11, 2013 and the change in fair value of the liability classified warrants as of December 31, 2013, June 10, 2014 (the date of exercise and issuance) and September 30, 2014 were determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models except that the exercise price resets at certain dates in the future. The values as of September 11, 2013, December 31, 2013, June 10, 2014 and September 30, 2014 were calculated based on the following assumptions:
		September 30, 2014			June 10, 2014			December 31, 2013			Initial Value
	Stock price	$	5.1		$	5.1		$	3.6		$	3.6
	Risk-free interest rate	1.43		%	1.32		%	1.75		%	1.72		%
	Expected volatility (peer group)	69.5		%	68.2		%	63.2		%	72.4		%
	Expected life (in years)	3.95			4.26			4.7			5
	Expected dividend yield	—			—			—			—
	Number outstanding	3,020,501			3,020,501			3,020,501			3,020,501
	Balance, end of period	$	9,594,000		$	9,714,000		$	5,928,000		$	6,860,000
Debt and Related Party Debt	'
	Debt and Related Party Debt — The Company accounts for the proceeds from the issuance of convertible notes payable with detachable stock purchase warrants and embedded conversion features in accordance with FASB ASC 470-20, Debt with Conversion and Other Options. Under FASB ASC 470-20, the proceeds from the issuance of a debt instrument with detachable stock purchase warrants is allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds allocated to the warrants is accounted for as additional paid-in capital and the remaining proceeds are allocated to the debt instrument, which results in a discount to debt that is amortized and charged as interest expense over the term of the note agreement. Additionally, pursuant to FASB ASC 470-20, the intrinsic value of the embedded conversion feature of the convertible notes payable is included in the discount to debt and amortized and charged to interest expense over the term of the note agreement. The following chart shows the effective interest rates on the original loan principal amount for loans originated in the respective periods that either had a beneficial conversion interest or an attached warrant:
	Type of Loan	Term of		Stated		Original			Conv.		Beneficial			Warrants	Exercise		Warrant		Effective
		Loan		Annual		Loan			Rate		Conversion			Issued with	Price		FMV		Interest Rate
				Interest		Principal					Discount			Notes			Discount		Including
				Rate		Amount					Amount						Amount		Discounts
	2013 convertible notes payable	1~2 years		10	%	$	3,079,666		$3.30		$	396,801		50,000	—		$	116,831	19.1% ~ 61.6%
	2014 convertible notes payable	6 mo.~ 2 years		10	%	859,320			$3.05 ~ $3.30		465,926			50,000	$	3.5	$	126,732	28.0% ~ 100.4%
	Total					$	3,938,986				$	862,727		100,000			$	243,563
	Related party notes are disclosed as separate line items in the Company’s balance sheet presentation.
Net loss per share	'
	Net loss per share — In accordance with FASB ASC Topic 260, Earnings per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Dilutive loss per share is computed in a manner similar to the basic loss per common share, except the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. As of September 30, 2014 and 2013, there were 13,993,997 and 13,811,989 shares of potentially dilutive securities outstanding, respectively. As the Company reported a net loss, none of the potentially dilutive securities were included in the calculation of diluted loss per share since their effect would be anti-dilutive for all periods presented.
Recent accounting pronouncements	'
	Recent accounting pronouncements — In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. This amendment will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. The core principle of the revenue recognition guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract(s); (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract(s); and (5) recognize revenue when (or as) the entity satisfies a performance obligation. For public companies, these amendments are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (early adoption prohibited). The standard permits the use of either the retrospective or cumulative effect transition method. Currently, the Company is assessing the impact of adoption of the amendment on its financial statements and accompanying notes.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern Sub-topic 205-40. The new guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. This ASU is effective for interim and annual periods beginning on or after December 15, 2016, and early adoption is permitted. The Company does not expect the adoption of this guidance to have a material impact on its financial position or results of operations.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Schedule of inventory purchases	'
	All of the raw material purchased during the nine months ended September 30, 2014 were from one vendor and during 2013 were from two vendors.
	Inventory by category	September 30, 2014			December 31, 2013
	Raw material	$	—		$	20,700
	Work-in-process	—			68,887
	Finished goods	223,780			149,422
		$	223,780		$	239,009
Schedule of changes in fair value of Level 3 liabilities	'
	The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs during the nine months ended September 30, 2014 and the year ended December 31, 2013:
		Liability Classified warrants –
		Stock Purchase Warrants
		September 30, 2014			December 31, 2013
	Balance, beginning of period	$	5,928,000		$	—
	Fair value at issuance date	3,523,000			6,860,000
	To reduce the warrants exercised to intrinsic value	(1,770,256		)	—
	To record settlement of liability associated with warrants exercised	(1,752,744		)	—
	Change in fair value included in the statement of comprehensive loss	3,666,000			(932,000		)
	Balance, end of period	$	9,594,000		$	5,928,000
Schedule of valuation assumptions for warrants	'
	The values as of September 11, 2013, December 31, 2013, June 10, 2014 and September 30, 2014 were calculated based on the following assumptions:
		September 30, 2014			June 10, 2014			December 31, 2013			Initial Value
	Stock price	$	5.1		$	5.1		$	3.6		$	3.6
	Risk-free interest rate	1.43		%	1.32		%	1.75		%	1.72		%
	Expected volatility (peer group)	69.5		%	68.2		%	63.2		%	72.4		%
	Expected life (in years)	3.95			4.26			4.7			5
	Expected dividend yield	—			—			—			—
	Number outstanding	3,020,501			3,020,501			3,020,501			3,020,501
	Balance, end of period	$	9,594,000		$	9,714,000		$	5,928,000		$	6,860,000
Schedule of convertible notes payable	'
	The following chart shows the effective interest rates on the original loan principal amount for loans originated in the respective periods that either had a beneficial conversion interest or an attached warrant:
	Type of Loan	Term of		Stated		Original			Conv.		Beneficial			Warrants	Exercise		Warrant		Effective
		Loan		Annual		Loan			Rate		Conversion			Issued with	Price		FMV		Interest Rate
				Interest		Principal					Discount			Notes			Discount		Including
				Rate		Amount					Amount						Amount		Discounts
	2013 convertible notes payable	1~2 years		10	%	$	3,079,666		$3.30		$	396,801		50,000	—		$	116,831	19.1% ~ 61.6%
	2014 convertible notes payable	6 mo.~ 2 years		10	%	859,320			$3.05 ~ $3.30		465,926			50,000	$	3.5	$	126,732	28.0% ~ 100.4%
	Total					$	3,938,986				$	862,727		100,000			$	243,563

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of property and equipment	'
	Property and equipment consisted of the following at:
		September 30, 2014			December 31, 2013
	Equipment	$	137,038		$	128,343
	Leasehold improvements	31,304			23,054
	Furniture and fixtures	60,194			52,269
	Sub total	228,536			203,666
	Less: accumulated depreciation	(189,312		)	(177,546		)
	Total	$	39,224		$	26,120

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets	'
	Intangible assets consisted of the following at:
		September 30, 2014			December 31, 2013
	License fees and patent filing costs	$	2,250,000		$	2,250,000
	Less: accumulated amortization	(1,303,571		)	(1,142,857		)
	Total	$	946,429		$	1,107,143
Schedule of estimated aggregate amortization expense for the next five years	'
	As of September 30, 2014, aggregate amortization expense for the next five years is estimated to be as follows:
	Periods ending December 31,	Amount
	2014 (fourth quarter)	$	53,572
	2015	214,286
	2016	214,286
	2017	214,286
	2018	214,286
	Thereafter	35,713
	Total	$	946,429

ACCOUNTS_PAYABLE_AND_ACCRUED_E1

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of accounts payable and accrued expenses	'
	Accounts payable and accrued expenses consisted of the following at:
		September 30, 2014		December 31, 2013
	Accounts payable
	Clinical trial management expenses	$	—	$	270,694
	Legal expenses	113,457		178,119
	Other vendors	541,388		386,847
	Subtotal	654,845		835,660
	Accrued interest payable, related parties	99,518		195,051
	Accrued interest payable	837,172		473,356
	Accrued expenses	180,075		294,379
	Deferred salary	291,667		485,000
	Total accounts payable and accrued expenses	$	2,063,277	$	2,283,446

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of notes payable	'
	Notes payable consisted of the following at September 30, 2014:
	Year	Interest		Term of Notes	Conv. Price	Principal		Discount		Carrying		Shares	Principal		Discount		Carrying		Shares
	Issued	rate				Outstanding		Amount		Amount		Underlying	Outstanding		Amount		Amount		Underlying
		range				September		September		September		Principal	December		December		December		Principal
						30, 2014		30, 2014		30, 2014		as of	31, 2013		31, 2013		31, 2013		as of
												September							December
												30, 2014							31, 2013
	Convertible notes payable
	2009	6.50%		5 years	$3.05	$	—	$	—	$	—	—	$	254,460	$	—	$	254,460	83,366
	2010	0 ~ 6.0%		5 years	$3.05	74,000		4,473		69,527		24,248	74,000		8,308		65,692		24,248
	2011	10%		5 years	$3.05	500,000		—		500,000		163,809	500,000		—		500,000		163,809
	2012	10%		2 years	$3.30 ~$3.60	201,600		—		201,600		56,000	251,100		—		251,100		71,000
	2013	10%		6 months ~ 2 years	$3.30 ~$3.60	4,599,445		32,687		4,566,758		1,307,922	6,913,606		215,798		6,697,808		1,998,215
	2014	10%		Due on demand ~ 2 years	$3.05 ~$7.00	2,720,412		121,296		2,599,116		578,832	—		—		—		—
						$	8,095,457	$	158,456	$	7,937,001	2,130,811	$	7,993,166	$	224,106	$	7,769,060	2,340,638
				Current		$	3,678,504	$	129,283	$	3,549,221	1,070,975	$	4,955,868	$	153,396	$	4,802,472	1,438,033
				Non-current		$	4,416,953	$	29,173	$	4,387,780	1,059,836	$	3,037,298	$	70,710	$	2,966,588	902,605
	Convertible notes payable - related party
	2012	10%		Due on demand	$3.30	$	373,000	$	—	$	373,000	113,030	$	373,000	$	—	$	373,000	113,030
	2013	10%		1 year	$3.60	152,066		—		152,066		42,241	187,706		—		187,706		52,141
	2014	10%		2 years	$7.00	200,000		—		200,000		28,571	—		—		—		—
						$	725,066	$	—	$	725,066	183,842	$	560,706	$	—	$	560,706	165,171
				Current		$	525,066	$	—	$	525,066	155,271	$	560,706	$	—	$	560,706	165,171
				Non-current		$	200,000	$	—	$	200,000	28,571	$	—	$	—	$	—	—
	Notes payable
	2012	11%		2 years	NA	$	—	$	—	$	—	—	$	833,335	$	18,265	$	815,070	—
	2013	2% ~ 10%		Due on demand ~ 2 years	NA	1,110,000		—		1,110,000		—	1,150,000		—		1,150,000		—
	2014	11%		2 years	NA	833,335		—		833,335		—	—		—		—		—
						$	1,943,335	$	—	$	1,943,335	—	$	1,983,335	$	18,265	$	1,965,070	—
				Current		$	1,110,000	$	—	$	1,110,000	—	$	1,783,335	$	18,265	$	1,765,070	—
				Non-current		$	833,335	$	—	$	833,335	—	$	200,000	$	—	$	200,000	—
	Notes payable - related party
	2012	8% ~ 10%		Due on demand	NA	$	656,730	$	—	$	656,730	—	$	880,062	$	4,421	$	875,641	—
	2013	8%		Due on demand	NA	50,000		—		50,000		—	50,000		—		50,000		—
	2014	11%		Due on demand ~ 2 years	NA	252,165		—		252,165		—	—		—		—		—
						$	958,895	$	—	$	958,895	—	$	930,062	$	4,421	$	925,641	—
				Current		$	825,562	$	—	$	825,562	—	$	930,062	$	4,421	$	925,641	—
				Non-current		$	133,333	$	—	$	133,333	—	$	—	$	—	$	—	—
				Grand Total		$	11,722,753	$	158,456	$	11,564,297	2,314,653	$	11,467,269	$	246,792	$	11,220,477	2,505,809
Schedule of contractual principal payments of loans and notes payable	'
	Contractual principal payments due on notes payable are as follows at September 30, 2014:
	In calendar year	Payments Due
	2014 (fourth quarter)	$	3,391,977
	2015	2,749,155
	2016	5,581,621
	Total	$	11,722,753

STOCKHOLDERS_EQUITY_DEFICIT_Ta

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of outstanding warrants	'
	A summary of outstanding warrants as of September 30, 2014 is presented below.
		Nine months ended		Year ended
		September 30, 2014		December 31, 2013
	Warrants outstanding, beginning of period	6,279,296		3,408,795
	Granted	1,145,465		3,370,501
	Exercised	(1,208,379	)	—
	Cancelled, forfeited and expired	(419,153	)	(500,000	)
	Warrants outstanding, end of period	5,797,229		6,279,296
	A summary of outstanding warrants by year issued and exercise price as of September 30, 2014 is presented below.
		Outstanding							Exercisable
	Year issued and	Number of		Weighted		Weighted			Total		Weighted
	Exercise Price	Warrants Issued		Average		Average					Average
				Remaining		Exercise Price					Exercise
				Contractual							Price
				Life (Years)
	Balance 2012
	$1.00	946,576		0.29		$	1		946,576		$	1
	$2.50	1,000,000		0.91		$	2.5		1,000,000		$	2.5
	$3.05	241,495		0.77		$	3.05		241,495		$	3.05
	75% of FMV	188,657		0.1		75% of FMV			188,657		75% of FMV
	2012 total	2,376,728							2,376,728
	During 2013
	$3.30	50,000		3.59		$	3.3		50,000		$	3.3
	$3.50	2,225,036		3.95		$	3.5		2,225,036		$	3.5
	2013 total	2,275,036							2,275,036
	During 2014
	$3.50	1,145,465		3.98		$	3.5		1,145,465		$	3.5
	Total	5,797,229							5,797,229
Schedule of stock option valuation assumptions	'
	The following table shows assumptions used on recent dates on which options were granted by the Board of Directors.
		July 17, 2014			May 8, 2014			February 26, 2014			July 18, 2013			February 28, 2013
	Stock price	$	5.1		$	4.9		$	3.6		$	3.6		$	3.6
	Exercise price	$	5.1		$	4.9		$	3.6		$	3.6		$	3.6
	Term	10 years			10 years			10 years			10 years			10 years
	Risk-Free Interest Rate	2.47		%	2.61		%	2.67		%	2.56		%	1.89		%
	Dividend Yield	0		%	0		%	0		%	0		%	0		%
	Volatility	77.9		%	75.5		%	76.6		%	113.6		%	119.3		%
Schedule of outstanding options	'
	A summary of outstanding options as of September 30, 2014 is presented below.
				2011 Stock Incentive Plan
		Prior Plan		September 30, 2014		December 31, 2013
	Options outstanding, beginning of period	11,795		4,504,000		1,199,000
	Granted	—		1,180,000		3,305,000
	Exercised	—		—		—
	Cancelled, forfeited and expired	—		(15,000	)	—
	Options outstanding, end of period	11,795		5,669,000		4,504,000

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of future minimum lease payments	'
	Future minimum lease payments under the agreements are as follows:
	2014	$	50,304
	2015	122,434
	2016	41,067
		$	213,805

RELATED_PARTY_TRANSACTIONS_Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Schedule of related parties outstanding loans	'
	The following table sets forth information relating to the Company’s loans from related persons outstanding as of September 30, 2014.
	Class	Lender	Interest		Date of	Term of Loan	Principal			Highest		Amount of					Amount of					Conv.		Shares
			rate		loan		Amount			Principal		Principal					Interest					Rate		underlying
							Outstanding			outstanding		Repaid					Paid							principal
							at																	at
							September 30,																	September 30,
							2014																	2014
	Current, Promissory note payable to related parties:
		Hope Int’l Hospice (1)	8	%	1/17/12	Due on demand	$	200,000		$	200,000	$	—				$		12,000			—		—
		Hope Int’l Hospice (1)	8	%	6/14/12	Due on demand	200,000			200,000		—					16,000					—		—
		Hope Int’l Hospice (1)	8	%	6/21/12	Due on demand	100,000			100,000		—					6,000					—		—
		Yutaka Niihara (2)(4)	10	%	12/5/12	Due on demand	156,730			1,213,700		1,056,970					60,851					—		—
		Hope Int’l Hospice (1)	8	%	2/11/13	Due on demand	50,000			50,000		—					3,000					—		—
		Lan T. Tran (2)	11	%	2/10/14	2 years (3)	106,976			106,976		—					—					—		—
		Cuc T. Tran (5)	11	%	3/5/14	1 year	11,856			11,856		—					—					—		—
						Sub total	$	825,562		$	1,882,532	$		1,056,970			$			97,851		—		—
	Current, Convertible notes payable to related parties:
		Yasushi Nagasaki (2)	10	%	6/29/12	Due on demand	$	373,000		$	388,800	$	15,800				$		67,680			$	3.3	113,030
		MLPF&S Cust. FBO Willis C.Lee (2)	10	%	10/5/13	1 year	152,066			152,066		—					—					$	3.6	42,241
						Sub total	$	525,066		$	540,866	$			15,800		$		67,680			—		155,271
	Long-term, Promissory note payable to related parties:
		Hideki & Eiko Uehara (5)	11	%	2/15/14	2 years	$	133,333		$	133,333	$	—				$		11,030			—		—
						Sub total	$	133,333		$	133,333	$	—				$	11,030				—		—
	Long-term, Convertible notes payable to related parties:
		Phillip M. Satow (4)	10	%	6/6/14	2 years	$	100,000		$	100,000	$	—				$		—			$	7	14,286
		Richard S. Pechter (5)	10	%	6/11/14	2 years	100,000			100,000		—					—					$	7	14,286
						Sub total	$	200,000		$	200,000	$	—				$		—			—		28,572
						Total	$	1,683,961		$	2,756,731	$	1,072,770				$		176,561			—		183,843
	(1)    Dr. Niihara is also the CEO of Hope International Hospice, Inc.
	(2)    Officer
	(3)    Due on demand
	(4)    Director
	(5)    Family of Officer/Director
	The following table sets forth information relating to the Company’s loans from related persons outstanding as of December 31, 2013.
	Class	Lender	Interest		Date of	Term of Loan	Principal			Highest		Amount of			Amount of			Conv.			Shares
			rate		loan		Amount			Principal		Principal			Interest			Rate			Underlying
							Outstanding			outstanding		Repaid			Paid						Principal
							as  of														as of
							December 31,														December
							2013														31, 2013
	Current, Promissory note payable to related parties:
		Hope Int’l Hospice(1)	8	%	1/17/12	Due on demand	$	200,000		$	200,000	$	—		$	20,000		—			—
		Lan T. Tran(2)	11	%	2/10/12	2 years(3)	80,000			205,000		125,000			—			—			—
		Hideki & Eiko Uehara(5)	11	%	2/15/12	2 years(3)	133,333			133,333		—			14,433			—			—
		Hope Int’l Hospice(1)	8	%	6/14/12	Due on demand	200,000			200,000		—			20,000			—			—
		Hope Int’l Hospice(1)	8	%	6/21/12	Due on demand	100,000			100,000		—			10,000			—			—
		Cuc T. Tran(5)	11	%	6/27/12	1 year	10,000			10,000		—			—			—			—
		Yutaka Niihara(2)(4)	10	%	12/5/12	Due on demand	156,730			1,213,700		1,056,970			—			—			—
		Hope Int’l Hospice(1)	8	%	2/11/13	Due on demand	50,000			50,000		—			3,000			—			—
						Sub total	$	930,063		$	2,112,033	$	1,181,970		$	67,433		—			—
						Less discount	$	(4,422	)
						Total	$	925,641
	Current, Convertible notes payable to related parties:
		Yasushi Nagasaki(2)	10	%	6/29/12	Due on demand	$	373,000		$	388,800	$	15,800		$	—		$	3.3		113,030
		Hideki & Eiko Uehara(5)	10	%	9/7/13	1 year	35,640			35,640		—			—			$	3.6		9,900
		MLPF&S Cust. FBO Willis C.Lee(2)(4)	10	%	10/5/13	1 year	152,066			152,066		—			—			$	3.6		42,240
						Sub total	$	560,706		$	576,506	$	15,800		$	—		—			165,170
						Total	$	1,486,347		$	2,688,539	$	1,197,770		$	67,433		—			165,170
	(1)    Dr. Niihara, who is the Company’s CEO, is also the CEO of Hope International Hospice, Inc.
	(2)    Officer
	(3)    Due on demand
	(4)    Director
	(5)    Family of Officer/Director

GEOGRAPHIC_INFORMATION_Tables

GEOGRAPHIC INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of revenue earned from countries outside of the United States	'
	The Company did not have any significant currency translation or foreign transaction adjustments during the nine months ended September 30, 2014 or 2013.
	Country	Sales nine months ended		% of Total revenue		Sales nine months ended		% of Total revenue
		September 30, 2014		nine months ended		September 30, 2013		nine months ended
				September 30, 2014				September 30, 2013
	Japan	$	132,145	38	%	$	125,590	51	%
	South Korea	45,312		13	%	—		—
	Taiwan	129,310		37	%	7,980		3	%

SUBSEQUENT_EVENTS_Tables

SUBSEQUENT EVENTS (Tables)	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Schedule of subsequent events notes payable	'
	A summary of these notes is as follows:
	Notes issued after	Loan Principal		Annual		Term of Notes	Conversion		Date of loan
	September 30, 2014	Outstanding		Interest Rate			Price
	Convertible note	$	2,136,146	10	%	2 years	$	3.6	10/10/14
	Promissory note	613,615		11	%	On demand up to 2 years	—		10/10/14
		$	2,749,761

AMOUNTS_RECLASSIFIED_OUT_OF_AC1

AMOUNTS RECLASSIFIED OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)	9 Months Ended
	Sep. 30, 2014
Amounts Reclassified Out Of Accumulated Other Comprehensive Income	'
Schedule of accumulated other comprehensive income (loss)	'
	The following tables show amounts added to and reclassified out of accumulated other comprehensive income:
		Unrealized holding			Unrealized			Total
		gain (loss) on			foreign
		securities			translation
		available-for-sale
	Balance — December 31, 2013	$	289,389		$	(26,706	)	$	262,683
	Other comprehensive income before reclassifications	(374,806		)	(5,681		)	(380,487		)
	Amounts reclassified from accumulated other comprehensive income	—			—			—
	Net current period other comprehensive income	(374,806		)	(5,681		)	(380,487		)
	Balance — September 30, 2014	$	(85,417	)	$	(32,387	)	$	(117,804	)
	Balance — December 31, 2012	$	(4,386	)	$	(8,046	)	$	(12,432	)
	Other comprehensive income before reclassifications	719,857			(34,381		)	685,476
	Amounts reclassified from accumulated other comprehensive income	—			—			—
	Net current period other comprehensive income	719,857			(34,381		)	685,476
	Balance — September 30, 2013	$	715,471		$	(42,427	)	$	673,044
	Amounts in parentheses indicate debits.
	All amounts are net of tax.

DESCRIPTION_OF_BUSINESS_Detail

DESCRIPTION OF BUSINESS (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2011	Oct. 31, 2010	Sep. 30, 2014
	Emmaus Medical Japan [Member]	Emmaus Medical Japan [Member]	Cellseed [Member]
Percentage Ownership	'	97.00%	1.00%
Aggregate formation cost of Emmaus Medical Japan, Inc	'	$52,500	'
Additional percentage of Emmaus Medical Japan, Inc. acquired	3.00%	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Jul. 30, 2013	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2009	Dec. 31, 2009	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
		JPY (¥)	USD ($)	USD ($)	USD ($)	JPY (¥)	JPY (¥)	2011 Convertible notes payable [Member]	2011 Convertible notes payable [Member]
								USD ($)	USD ($)
Advertising Costs	'	'	$185,465	$161,301	'	'	'	'	'
Shares of CellSeed held as marketable securities	'	'	'	'	'	'	48,550	'	'
CellSeed, shares originally purchased (in shares)	'	'	'	'	'	'	147,100	'	'
CellSeed Investment, in Yen	'	'	'	'	'	100,028,000	'	'	'
CellSeed Investment, in Dollars	'	'	'	'	1,109,819	'	'	'	'
CellSeed Investment, in Yen per share	'	'	'	'	'	¥ 680	'	'	'
CellSeed Investment, closing price in Yen	'	¥ 1,840	'	'	'	'	¥ 1,072	'	'
Cellseed shares released from Mitsubishi Capital collateral	34,300	'	'	'	'	'	'	'	'
Convertible notes payable, Carrying Amount	'	'	'	'	'	'	'	$500,000	$500,000
Shares of Cellseed sold	73,550	25,000	'	'	'	'	'	'	'
Available for sale securities, CellSeed stock (in shares)	'	9,300	'	'	'	'	9,300	'	'
CellSeed stock pledged against note	'	39,250	'	'	'	'	'	'	'
Potentially Antidilutive Shares (in shares)	'	'	13,993,997	13,811,989	'	'	'	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory:	'	'
Raw materials and components	'	$20,700
Work-in-process	'	68,887
Finished goods	223,780	149,422
Total	$223,780	$239,009

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	3 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013
					Warrants [Member]	Warrants [Member]
Liability Classified Warrants - Stock Purchase Warrants, beginning	'	'	'	'	$5,928,000	'
Fair value at issuance date	'	'	'	'	3,523,000	6,860,000
To reduce the warrants exercised to intrinsic value	'	'	'	'	-1,770,256	'
To record settlement of liability associated with warrants exercised	'	'	'	'	-1,752,744	'
Change in fair value included in the statement of comprehensive loss	-84,000	-291,000	1,895,744	-291,000	3,750,000	-932,000
Liability Classified Warrants - Stock Purchase Warrants, ending	'	'	'	'	$9,678,000	$5,928,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	0 Months Ended						0 Months Ended	9 Months Ended	12 Months Ended
	Jun. 10, 2014	Jul. 17, 2014	8-May-14	Feb. 26, 2014	Jul. 18, 2013	Feb. 28, 2013	Sep. 11, 2013	Sep. 30, 2014	Dec. 31, 2013
							Warrants [Member]	Warrants [Member]	Warrants [Member]
Stock price	$5.10	$5.10	$4.90	$3.60	$3.60	$3.60	$3.60	$5.10	$3.60
Risk Free Interest Rate	1.32%	'	'	'	'	'	1.72%	1.43%	1.75%
Expected volatility (peer group)	68.20%	'	'	'	'	'	72.40%	6.95%	63.20%
Expected life	'4 years 3 months 4 days	'	'	'	'	'	'5 years	'3 years 11 months 12 days	'4 years 8 months 12 days
Number outstanding	3,020,501	'	'	'	'	'	3,020,501	3,020,501	3,020,501
Fair value at issuance	$9,714,000	'	'	'	'	'	$6,860,000	$9,594,000	$5,928,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) (USD $)	Jun. 10, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
		Lower Range [Member]	Upper Range [Member]	2013 Convertible notes payable - related party [Member]	2013 Convertible notes payable - related party [Member]	2013 Convertible notes payable - related party [Member]	2014 Convertible notes payable - related party [Member]	2014 Convertible notes payable - related party [Member]	2014 Convertible notes payable - related party [Member]	Notes payable and convertible notes payable - related party [Member]
					Lower Range [Member]	Upper Range [Member]		Lower Range [Member]	Upper Range [Member]
Term of Loan	'	'	'	'	'1 year	'2 years	'2 years	'6 months	'2 years	'
Annual interest rate	'	'	'	10.00%	'	'	10.00%	'	'	'
Original Loan Principal Amount	'	'	'	$3,079,666	'	'	$859,320	'	'	$3,938,986
Conversion rate (in dollars per share)	'	$3.05	$7	$3.30	'	'	$7	$3.05	$3.30	'
Beneficial Conversion Discount Amount	'	'	'	396,801	'	'	465,926	'	'	862,727
Warrants	3,020,501	'	'	50,000	'	'	50,000	'	'	100,000
Warrant strike price	'	'	'	'	'	'	$3.50	'	'	'
Warrant FMV Discount Amount	'	'	'	$116,831	'	'	$126,732	'	'	$243,563
Effective Interest Rate Including Discounts	'	'	'	'	19.10%	61.60%	'	28.00%	100.40%	'

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'	'
Depreciation Expense	$11,999	$17,172

PROPERTY_AND_EQUIPMENT_Details1

PROPERTY AND EQUIPMENT (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property and equipment	'	'
Property and equipment, gross	$228,535	$203,666
Less: accumulated depreciation	-189,312	-177,546
Property and equipment, net	39,224	26,120
Equipment [Member]	'	'
Property and equipment	'	'
Property and equipment, gross	137,038	128,343
Leasehold Improvements [Member]	'	'
Property and equipment	'	'
Property and equipment, gross	31,304	23,054
Furniture and Fixtures [Member]	'	'
Property and equipment	'	'
Property and equipment, gross	$60,194	$52,269

INTANGIBLE_ASSETS_Details_Narr

INTANGIBLE ASSETS (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Individual Agreement with CellSeed	$1,500,000	'
Research Agreement with CellSeed	8,500,000	'
Amortization expense	$160,714	$160,714

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Intangible assets	'	'
License fees and patent filing costs	$2,250,000	$2,250,000
Less: accumulated amortization	-1,303,571	-1,142,857
Intangibles, net	$946,429	$1,107,143

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Year ending December 31	'	'
2014	$53,572	'
2015	214,286	'
2016	214,286	'
2017	214,286	'
2018	214,286	'
Thereafter	35,713	'
Intangibles, net	$946,429	$1,107,143

ACCOUNTS_PAYABLE_AND_ACCRUED_E2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accounts payable and accrued expenses	'	'
Clinical trial management expenses	'	$270,694
Legal Expenses	113,457	178,119
Other vendors	541,388	386,847
Subtotal	654,845	835,660
Accrued interest payable, related parties	99,518	195,051
Accrued interest payable	837,172	473,356
Accrued expenses	180,075	294,379
Deferred salary	291,667	485,000
Total accounts payable and accrued expenses	$2,063,277	$2,283,446

NOTES_PAYABLE_Details_Narrativ

NOTES PAYABLE (Details Narrative) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Average stated interest rate	10.00%	10.00%
Average effective interest rate	16.00%	15.00%
Lower Range [Member]	'	'
Conversion price	3.05	'
Upper Range [Member]	'	'
Conversion price	7	'

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Principal Outstanding	$11,722,753	$11,467,269
Discount Amount	158,456	246,792
Notes payable related parties, Carrying Amount	'	11,220,477
Total Carrying Amount	11,564,297	'
Shares Underlying Principal	2,314,653	2,505,809
Convertible notes payable, Current	3,549,221	4,802,472
Convertible notes payable, Non Current	4,387,780	2,966,588
Notes payable, Current	1,110,000	1,765,070
Notes payable, Non Current	833,335	200,000
Notes payable related parties, Current	825,562	925,641
Notes payable related parties, Non Current	133,333	'
Lower Range [Member]	'	'
Conversion price	$3.05	'
Upper Range [Member]	'	'
Conversion price	$7	'
2009 Convertible notes payable [Member]	'	'
Interest rate	6.50%	'
Term of Notes	'5 years	'
Conversion price	$3.05	'
Principal Outstanding	'	254,460
Convertible notes payable, Carrying Amount	'	254,460
Shares Underlying Principal	'	83,366
2010 Convertible notes payable [Member]	'	'
Interest rate range, Minimum	0.00%	'
Interest rate range, Maximum	6.00%	'
Term of Notes	'5 years	'
Conversion price	$3.05	'
Principal Outstanding	74,000	74,000
Discount Amount	4,473	8,308
Convertible notes payable, Carrying Amount	69,527	65,692
Shares Underlying Principal	24,248	24,248
2011 Convertible notes payable [Member]	'	'
Interest rate	10.00%	'
Term of Notes	'5 years	'
Conversion price	$3.05	'
Principal Outstanding	500,000	500,000
Convertible notes payable, Carrying Amount	500,000	500,000
Shares Underlying Principal	163,809	163,809
2012 Convertible notes payable [Member]	'	'
Interest rate	10.00%	'
Term of Notes	'2 years	'
Conversion price, minimum	$3.30	'
Conversion price, maximum	$3.60	'
Principal Outstanding	201,600	251,100
Convertible notes payable, Carrying Amount	201,600	251,100
Shares Underlying Principal	56,000	71,000
2012 Convertible notes payable [Member] | Lower Range [Member]	'	'
Term of Notes	'Due on demand	'
2013 Convertible notes payable [Member]	'	'
Interest rate	10.00%	'
Conversion price, minimum	$3.30	'
Conversion price, maximum	$3.60	'
Principal Outstanding	4,599,445	6,913,606
Discount Amount	32,687	215,798
Convertible notes payable, Carrying Amount	4,566,758	6,697,808
Shares Underlying Principal	1,307,922	1,998,215
2013 Convertible notes payable [Member] | Lower Range [Member]	'	'
Term of Notes	'6 months	'
2013 Convertible notes payable [Member] | Upper Range [Member]	'	'
Term of Notes	'2 years	'
2014 Convertible notes payable [Member]	'	'
Interest rate	10.00%	'
Conversion price, minimum	$3.05	'
Conversion price, maximum	$7	'
Principal Outstanding	2,720,412	'
Discount Amount	121,296	'
Convertible notes payable, Carrying Amount	2,599,116	'
Shares Underlying Principal	578,832	'
2014 Convertible notes payable [Member] | Upper Range [Member]	'	'
Term of Notes	'2 years	'
Convertible notes payable [Member]	'	'
Principal Outstanding	8,095,457	7,993,166
Discount Amount	158,456	224,106
Convertible notes payable, Carrying Amount	7,937,001	7,769,060
Shares Underlying Principal	2,130,811	2,340,638
Principal Outstanding, Current	3,678,504	4,955,868
Principal Outstanding, Non Current	4,416,953	3,037,298
Discount Amount Current	129,283	153,396
Discount Amount Non Current	29,173	70,710
Convertible notes payable, Current	3,549,221	4,802,472
Convertible notes payable, Non Current	4,387,780	2,966,588
Shares Underlying Principal Current	1,070,975	1,438,033
Shares Underlying Principal Non Current	1,059,836	902,605
2012 Convertible notes payable - related party [Member]	'	'
Interest rate	10.00%	'
Term of Notes	'DUE ON DEMAND	'
Conversion price	$3.30	'
Principal Outstanding	373,000	373,000
Convertible notes payable related parties, Carrying Amount	373,000	373,000
Shares Underlying Principal	113,030	113,030
2013 Convertible notes payable - related party [Member]	'	'
Interest rate	10.00%	'
Term of Notes	'1 year	'
Conversion price	$3.60	'
Principal Outstanding	152,066	187,706
Convertible notes payable related parties, Carrying Amount	152,066	187,706
Shares Underlying Principal	42,241	52,141
2014 Convertible notes payable - related party [Member]	'	'
Interest rate	10.00%	'
Term of Notes	'2 years	'
Conversion price	$7	'
Principal Outstanding	200,000	'
Convertible notes payable related parties, Carrying Amount	200,000	'
Shares Underlying Principal	28,571	'
2014 Convertible notes payable - related party [Member] | Lower Range [Member]	'	'
Term of Notes	'6 months	'
Conversion price	$3.05	'
2014 Convertible notes payable - related party [Member] | Upper Range [Member]	'	'
Term of Notes	'2 years	'
Conversion price	$3.30	'
Convertible notes payable - related party [Member]	'	'
Principal Outstanding	725,066	560,706
Convertible notes payable related parties, Carrying Amount	725,066	560,706
Total Carrying Amount	525,066	560,706
Shares Underlying Principal	155,271	165,171
Principal Outstanding, Current	526,066	560,706
Principal Outstanding, Non Current	200,000	'
Convertible notes payable related parties, Current	525,066	560,706
Convertible notes payable related parties, Non Current	200,000	'
Shares Underlying Principal Current	155,271	165,171
Shares Underlying Principal Non Current	28,571	'
2012 Notes payable [Member]	'	'
Interest rate	11.00%	'
Term of Notes	'2 years	'
Principal Outstanding	'	833,335
Discount Amount	'	18,265
Notes payable, Carrying Amount	'	815,070
2013 Notes payable [Member]	'	'
Interest rate range, Minimum	2.00%	'
Interest rate range, Maximum	10.00%	'
Principal Outstanding	1,110,000	1,150,000
Notes payable, Carrying Amount	1,110,000	1,150,000
2013 Notes payable [Member] | Lower Range [Member]	'	'
Term of Notes	'Due on demand	'
2013 Notes payable [Member] | Upper Range [Member]	'	'
Term of Notes	'2 years	'
2014 Notes payable [Member]	'	'
Interest rate	11.00%	'
Term of Notes	'2 years	'
Principal Outstanding	833,335	'
Notes payable, Carrying Amount	833,335	'
Notes Payable [Member]	'	'
Principal Outstanding	1,943,335	1,983,335
Discount Amount	'	18,265
Notes payable, Carrying Amount	1,943,335	1,965,070
Principal Outstanding, Current	1,110,000	1,783,335
Principal Outstanding, Non Current	833,335	200,000
Discount Amount Current	'	18,265
Notes payable, Current	1,110,000	1,765,070
Notes payable, Non Current	833,335	200,000
2012 Notes payable - related party [Member]	'	'
Interest rate range, Minimum	8.00%	'
Interest rate range, Maximum	10.00%	'
Term of Notes	'Due on demand	'
Principal Outstanding	656,730	880,062
Discount Amount	'	4,421
Notes payable related parties, Carrying Amount	656,730	875,641
2013 Notes payable - related party [Member]	'	'
Interest rate	8.00%	'
Term of Notes	'Due on demand	'
Principal Outstanding	50,000	50,000
Notes payable related parties, Carrying Amount	50,000	50,000
2014 Notes payable - related party [Member]	'	'
Interest rate	11.00%	'
Principal Outstanding	252,165	'
Notes payable related parties, Carrying Amount	252,165	'
2014 Notes payable - related party [Member] | Lower Range [Member]	'	'
Term of Notes	'Due on demand	'
2014 Notes payable - related party [Member] | Upper Range [Member]	'	'
Term of Notes	'2 years	'
Notes payable - related party [Member]	'	'
Principal Outstanding	958,895	930,062
Discount Amount	'	4,421
Notes payable related parties, Carrying Amount	958,895	925,641
Total Carrying Amount	825,562	930,063
Principal Outstanding, Current	825,562	930,062
Principal Outstanding, Non Current	133,333	'
Discount Amount Current	'	4,421
Notes payable related parties, Current	825,562	925,641
Notes payable related parties, Non Current	$133,333	'

NOTES_PAYABLE_Details_1

NOTES PAYABLE (Details 1) (USD $)	Sep. 30, 2014
Contractual principal payments due on loans and notes payable for the year ending	'
2014	$3,391,977
2015	2,749,155
2016	5,581,621
Total	$11,722,753

STOCKHOLDERS_EQUITY_DEFICIT_De

STOCKHOLDERS' EQUITY (DEFICIT) (Details Narrative) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Jul. 17, 2014

Jun. 10, 2014

8-May-14

Feb. 26, 2014

Dec. 31, 2013

Jul. 18, 2013

Feb. 28, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 11, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Common stock - par value $0.001 per share,100,000,000 shares authorized [Member]

Common stock - par value $0.001 per share,100,000,000 shares authorized [Member]

Stock Options [Member]

Stock Options - Tranche 1 [Member]

Stock Options - Tranche 2 [Member]

Stock Options - Tranche 3 [Member]

2014 Convertible notes payable - related party [Member]

Warrants [Member]

Warrants [Member]

Warrants [Member]

Warrants [Member]

Warrants [Member]

Warrants Granted in 2014 - $3.50 Exercise Price [Member]

Warrants Exercised in 2014 [Member]

Warrants Exercised in 2014 [Member]

Warrants Exercised in 2014 [Member]

Private Placement [Member]

Registration Placement - Resale [Member]

Registration Placement - Resale [Member]

Director [Member]

Lower Range [Member]

Upper Range [Member]

Numbers of units issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,020,501

Share price (in dollars per share)

'

'

'

'

$5.10

$5.10

$4.90

$3.60

'

$3.60

$3.60

'

'

'

'

'

'

'

$5.10

$3.60

$3.60

'

'

'

'

'

'

$2.50

Composition of units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'One share of common stock and one common stock warrant

Purchase price of units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7,551,253

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.50

'

$3.30

'

'

$1

$3.50

'

$3.50

$3.83

$3.50

Number of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

50,000

'

3,320,501

'

'

'

'

'

'

Warrants expired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

Warrant term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

Proceeds from exercise of warrants

'

'

4,217,078

'

'

'

'

'

'

'

'

1,208

'

'

'

'

'

'

'

'

'

'

'

'

3,867,852

'

'

'

Proceeds from exercise of warrants, shares

'

'

'

'

'

'

'

'

'

'

'

1,208,379

'

'

'

'

'

'

'

'

'

'

'

'

112,914

'

'

'

Warrants granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,095,465

'

'

'

'

Excess value of liability classified warrants upon exercise

'

'

1,752,744

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise inducement expense

'

'

-3,523,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of warrants, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,246

'

'

'

Options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

840,000

438,000

302,000

100,000

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.60

$4.90

$5.10

'

'

'

'

'

'

'

'

'

'

'

Vesting terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Vest over three years starting February 26, 2015

'Vest over three years starting May 8, 2015

'Vest over three years starting July 15, 2015

'

'

'

'

'

'

'

'

'

'

'

Options issuable

'

'

'

'

'

'

'

'

'

'

'

'

'

340,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options issuable

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock authorized

100,000,000

'

100,000,000

'

'

'

'

'

100,000,000

'

'

'

4,115,966

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Resale agreement number of shares to be registered by September 11, 2014

'

'

'

'

'

'

'

'

'

'

'

'

2,225,036

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Resale agreement number of shares to be registered by June 10, 2015

'

'

'

'

'

'

'

'

'

'

'

'

1,095,465

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STOCKHOLDERS_EQUITY_DEFICIT_De1

STOCKHOLDERS' EQUITY (DEFICIT) (Details)	Jun. 10, 2014	Sep. 30, 2014	Dec. 31, 2013
		Warrants [Member]	Warrants [Member]
Warrants outstanding summary	'	'	'
Warrants outstanding, beginning of period	3,020,501	6,279,296	3,408,795
Granted	'	1,145,465	3,370,501
Exercised	'	-1,208,379	'
Cancelled, forfeited and expired	'	-419,153	-500,000
Warrants outstanding, end of period	3,020,501	5,797,229	6,279,296

STOCKHOLDERS_EQUITY_DEFICIT_De2

STOCKHOLDERS' EQUITY (DEFICIT) (Details 1) (USD $)

Jun. 10, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Warrants Issued in 2012 - Exercise Price $1.00 [Member]

Warrants Issued in 2012 - Exercise Price $2.50 [Member]

Warrants Issued in 2012 - Exercise Price $3.05 [Member]

Warrants Issued in 2012 - Exercise Price 75% of FMV [Member]

Warrants Issued in 2012 [Member]

Warrants Issued in 2013 - Exercise Price $3.30 [Member]

Warrants Issued in 2013 - Exercise Price $3.50 [Member]

Warrants Issued in 2013 [Member]

Warrants Granted in 2014 - $3.50 Exercise Price [Member]

Warrants [Member]

Warrants [Member]

Warrants [Member]

Year Issued

'

'2012

'2012

'2012

'2012

'

'2013

'2013

'

'2014

'

'

'

Weighted Average Exercise Price

'

$1

$2.50

$3.05

'

'

$3.30

$3.50

'

$3.50

'

'

'

Weighted Average Exercise Price, textual reference

'

'

'

'

'75% of FMV

'

'

'

'

'

'

'

'

Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Warrants

3,020,501

946,576

1,000,000

241,495

188,657

2,376,728

50,000

2,225,036

2,275,036

1,145,465

5,797,229

6,279,296

3,408,795

Weighted Average Remaining Contractual Life (Years)

'

'0 years 3 months 14 days

'0 years 10 months 28 days

'0 years 9 months 7 days

'0 years 1 month 6 days

'

'3 years 7 months 2 days

'3 years 11 months 12 days

'

'3 years 6 months

'

'

'

Exercisable

'

'

'

'

'

'

'

'

'

'

'

'

'

Total

'

946,576

1,000,000

241,495

188,657

2,376,728

50,000

2,225,036

2,275,036

1,145,465

5,797,229

'

'

STOCKHOLDERS_EQUITY_DEFICIT_De3

STOCKHOLDERS' EQUITY (DEFICIT) (Details 2) (USD $)	0 Months Ended
	Jul. 17, 2014	8-May-14	Feb. 26, 2014	Jul. 18, 2013	Feb. 28, 2013	Jun. 10, 2014
Stockholders' Equity Note [Abstract]	'	'	'	'	'	'
Stock price	$5.10	$4.90	$3.60	$3.60	$3.60	$5.10
Exercise price	$5.10	$4.90	$3.60	$3.60	$3.60	'
Term	'10 years	'10 years	'10 years	'10 years	'10 years	'
Risk-Free Rate	2.47%	2.61%	2.67%	2.56%	1.89%	'
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	'
Volatility	77.90%	75.50%	76.60%	113.60%	119.30%	'

STOCKHOLDERS_EQUITY_DEFICIT_De4

STOCKHOLDERS' EQUITY (DEFICIT) (Details 3) (Stock Options [Member])	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Stock options outstanding	'	'
Options Granted	840,000	'
Prior Plan [Member]	'	'
Stock options outstanding	'	'
Options outstanding, ending	11,795	11,795
2011 Stock Incentive Option Plan [Member]	'	'
Stock options outstanding	'	'
Options outstanding, beginning	4,504,000	1,199,000
Options Granted	1,180,000	3,305,000
Options cancelled, forfeited and expired	-15,000	'
Options outstanding, ending	5,669,000	4,504,000

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'
Monthly commercialization management fee	$5,000	'
Rent expense	$163,605	$101,891

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Sep. 30, 2014
Future minimum lease payments	'
2014	$50,304
2015	122,434
2016	41,067
Total Future Minimum Lease Payments Due	$213,805

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Narrative)	0 Months Ended
	Jun. 27, 2013
Related Party Transactions [Abstract]	'
Number of shares cancelled	2,504,249

RELATED_PARTY_TRANSACTIONS_Det1

RELATED PARTY TRANSACTIONS (Details) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014		Dec. 31, 2013
Principal Amount Outstanding	$11,564,297		'
Shares Underlying Principal	2,314,653		2,505,809
Less discount	-158,456		-246,792
Total	11,722,753		'
Hope Intl Hospice [Member]	'		'
Annual Interest Rate	8.00%		8.00%	[1]
Date of Loan	17-Jan-12	[1]	17-Jan-12	[1]
Term of Loan	'On demand	[1]	'On Demand	[1]
Principal Amount Outstanding	200,000		200,000	[1]
Highest Principal Outstanding	200,000	[1]	200,000	[1]
Amount of Interest Paid	12,000	[1]	20,000	[1]
Hope Intl Hospice [Member]	'		'
Annual Interest Rate	8.00%		8.00%	[1]
Date of Loan	14-Jun-12	[1]	14-Jun-12	[1]
Term of Loan	'On Demand	[1]	'On Demand	[1]
Principal Amount Outstanding	200,000		200,000	[1]
Highest Principal Outstanding	200,000	[1]	200,000	[1]
Amount of Interest Paid	16,000	[1]	20,000	[1]
Hope Int'l Hospice [Member]	'		'
Annual Interest Rate	8.00%	[1]	'
Date of Loan	21-Jun-12	[1]	'
Term of Loan	'On Demand	[1]	'
Principal Amount Outstanding	100,000	[1]	'
Highest Principal Outstanding	100,000	[1]	'
Amount of Interest Paid	6,000	[1]	'
Yutaka Niihara [Member]	'		'
Annual Interest Rate	1.00%	[2],[3]	'
Date of Loan	5-Dec-12	[2],[3]	'
Term of Loan	'On Demand	[2],[3]	'
Principal Amount Outstanding	156,730	[2],[3]	'
Highest Principal Outstanding	1,213,700	[2],[3]	'
Amount of Principal Repaid	1,056,970	[2],[3]	'
Amount of Interest Paid	60,851	[2],[3]	'
Hope Intl Hospice [Member]	'		'
Annual Interest Rate	8.00%		8.00%	[1]
Date of Loan	11-Feb-13	[1]	21-Jun-12	[1]
Term of Loan	'On Demand	[1]	'On Demand	[1]
Principal Amount Outstanding	50,000		100,000	[1]
Highest Principal Outstanding	50,000	[1]	100,000	[1]
Amount of Interest Paid	3,000	[1]	10,000	[1]
Lan T. Tran [Member]	'		'
Annual Interest Rate	11.00%		11.00%	[2]
Date of Loan	10-Feb-14	[2]	10-Feb-12	[2]
Term of Loan	'2 years	[2],[4]	'2 years	[2],[4]
Principal Amount Outstanding	106,976		80,000	[2]
Highest Principal Outstanding	106,976	[2]	205,000	[2]
Amount of Principal Repaid	'		125,000	[2]
Cuc T. Tran [Member]	'		'
Annual Interest Rate	11.00%		11.00%
Date of Loan	5-Mar-14	[5]	27-Jun-12	[5]
Term of Loan	'1 year	[5]	'1 year	[5]
Principal Amount Outstanding	11,856		10,000
Highest Principal Outstanding	11,856	[5]	10,000	[5]
Notes payable - related party [Member]	'		'
Principal Amount Outstanding	825,562		930,063
Highest Principal Outstanding	1,882,532		2,112,033
Amount of Principal Repaid	1,056,970		1,181,970
Amount of Interest Paid	97,851		67,433
Less discount	'		-4,421
Total	'		925,641
Yasushi Nagasaki [Member]	'		'
Annual Interest Rate	10.00%		10.00%
Date of Loan	29-Jun-12	[2]	29-Jun-12	[2]
Term of Loan	'On Demand	[2]	'On Demand	[2]
Principal Amount Outstanding	373,000		373,000
Highest Principal Outstanding	388,800	[2]	388,800	[2]
Amount of Principal Repaid	15,800	[2]	15,800	[2]
Amount of Interest Paid	67,680	[2]	'
Debt conversion price	$3.30	[2]	$3.30	[2]
Shares Underlying Principal	113,030	[2]	113,030	[2]
MLPF&S Cust. FBO Willis C.Lee [Member]	'		'
Annual Interest Rate	10.00%	[2]	10.00%	[2],[3]
Date of Loan	5-Oct-13	[2]	5-Oct-13	[2],[3]
Term of Loan	'1 year	[2]	'1 year	[2],[3]
Principal Amount Outstanding	152,066	[2]	152,066	[2],[3]
Highest Principal Outstanding	152,066	[2]	152,066	[2],[3]
Debt conversion price	$3.60	[2]	$3.60	[2],[3]
Shares Underlying Principal	42,241	[2]	42,240	[2],[3]
Convertible notes payable - related party [Member]	'		'
Principal Amount Outstanding	525,066		560,706
Highest Principal Outstanding	540,866		576,506
Amount of Principal Repaid	15,800		15,800
Amount of Interest Paid	67,680		'
Shares Underlying Principal	155,271		165,171
Hideki and Eiko Uehara [Member]	'		'
Annual Interest Rate	11.00%	[5]	10.00%
Date of Loan	15-Feb-14	[5]	7-Sep-13	[5]
Term of Loan	'2 years	[5]	'1 year	[5]
Principal Amount Outstanding	133,333	[5]	35,640
Highest Principal Outstanding	133,333	[5]	35,640	[5]
Amount of Interest Paid	11,030	[5]	'
Debt conversion price	'		$3.60	[5]
Shares Underlying Principal	'		9,900	[5]
Long-term promissory note payable to related parties [Member]	'		'
Principal Amount Outstanding	133,333		'
Highest Principal Outstanding	133,333		'
Amount of Interest Paid	11,030		'
Phillip M. Satow [Member]	'		'
Annual Interest Rate	10.00%	[3]	'
Date of Loan	6-Jun-14	[3]	'
Term of Loan	'2 years	[3]	'
Principal Amount Outstanding	100,000	[3]	'
Highest Principal Outstanding	100,000	[3]	'
Debt conversion price	$7	[3]	'
Shares Underlying Principal	14,286	[3]	'
Richard S. Pechter [Member]	'		'
Annual Interest Rate	10.00%	[5]	'
Date of Loan	11-Jun-14	[5]	'
Term of Loan	'2 years	[5]	'
Principal Amount Outstanding	100,000	[5]	'
Highest Principal Outstanding	100,000	[5]	'
Debt conversion price	$7	[5]	'
Shares Underlying Principal	14,286	[5]	'
Long-term convertible notes payable - related party [Member]	'		'
Principal Amount Outstanding	200,000	[5]	'
Highest Principal Outstanding	200,000	[5]	'
Shares Underlying Principal	28,572		'
Notes payable and convertible notes payable - related party [Member]	'		'
Principal Amount Outstanding	1,683,961		1,486,347
Highest Principal Outstanding	2,756,731		2,688,539
Amount of Principal Repaid	1,072,770		1,197,770
Amount of Interest Paid	176,561		67,433
Shares Underlying Principal	183,843		165,170
Hideki and Eiko Uehara [Member]	'		'
Annual Interest Rate	'		11.00%	[5]
Date of Loan	'		15-Feb-12	[5]
Term of Loan	'		'2 years	[4],[5]
Principal Amount Outstanding	'		133,333	[5]
Highest Principal Outstanding	'		133,333	[5]
Amount of Interest Paid	'		14,433	[5]
Yutaka Niihara [Member]	'		'
Annual Interest Rate	'		10.00%
Date of Loan	'		5-Dec-12	[2],[3]
Term of Loan	'		'On Demand	[2],[3]
Principal Amount Outstanding	'		156,730
Highest Principal Outstanding	'		1,213,700	[2],[3]
Amount of Principal Repaid	'		1,056,970	[2],[3]
Hope Intl Hospice [Member]	'		'
Annual Interest Rate	'		8.00%
Date of Loan	'		11-Feb-13	[1]
Term of Loan	'		'On Demand	[1]
Principal Amount Outstanding	'		50,000
Highest Principal Outstanding	'		50,000	[1]
Amount of Interest Paid	'		$3,000	[1]
[1]	Dr. Niihara, who is the Company's CEO, is also the CEO of Hope International Hospice, Inc.
[2]	Officer
[3]	Director
[4]	Due on Demand
[5]	Family of Officer/Director

GEOGRAPHIC_INFORMATION_Details

GEOGRAPHIC INFORMATION (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Japan [Member]	'	'
Company revenue earned from countries outside of the U.S.	'	'
Revenue	$132,145	$125,590
Percentage of revenue (in percent)	38.00%	51.00%
South Korea [Member]	'	'
Company revenue earned from countries outside of the U.S.	'	'
Revenue	45,312	'
Percentage of revenue (in percent)	24.00%	'
Taiwan [Member]	'	'
Company revenue earned from countries outside of the U.S.	'	'
Revenue	$129,310	$7,980
Percentage of revenue (in percent)	37.00%	3.00%

SUBSEQUENT_EVENTS_Details_Narr

SUBSEQUENT EVENTS (Details Narrative) (USD $)	9 Months Ended			1 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Oct. 31, 2014	Oct. 31, 2014
				Subsequent Event [Member]	Subsequent Event [Member]
				sqft	2014 Notes payable [Member]
Conversion of notes payable to common stock	$1,404,552	$2,606,100	'	$131,717	'
Debt conversion price	'	'	'	$3.60	$3.60
Warrants exercised	'	'	'	35,556	'
Warrant exercise price	'	'	'	$1	'
Accrued interest	180,075	'	294,379	'	213,615
Additional loan proceeds	'	'	'	'	400,000
Lease inception date	'	'	'	14-Nov-14	'
Lease expiration date	'	'	'	28-Feb-19	'
Lease square footage	'	'	'	13,329	'
Monthly base rent	'	'	'	36,370	'
Total Future Minimum Lease Payments Due	$213,805	'	'	$1,873,075	'

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Oct. 31, 2014	Sep. 30, 2014	Oct. 31, 2014	Sep. 30, 2014	Oct. 31, 2014
			Subsequent Event [Member]	2014 Notes payable [Member]	2014 Notes payable [Member]	2014 Convertible notes payable - related party [Member]	2014 Convertible notes payable - related party [Member]
					Subsequent Event [Member]		Subsequent Event [Member]
Principal Outstanding	$11,722,753	$11,467,269	'	$833,335	$2,136,146	$200,000	$613,615
Interest rate	'	'	'	11.00%	10.00%	10.00%	11.00%
Term of Notes	'	'	'	'	'2 years	'	'On demand up to 2 years
Conversion price	'	'	$3.60	'	$3.60	$7	'
Date of Loan	'	'	'	'	10-Oct-14	'	10-Oct-14

AMOUNTS_RECLASSIFIED_OUT_OF_AC2

AMOUNTS RECLASSIFIED OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]	'	'
Balance - beginning	$289,389	($4,386)
Other comprehensive income before reclassifications	-374,806	719,857
Net current period other comprehensive income	-374,806	719,857
Balance - end	-85,417	715,471
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]	'	'
Balance - beginning	-26,706	-8,046
Other comprehensive income before reclassifications	-5,681	-34,381
Net current period other comprehensive income	-5,681	-34,381
Balance - end	-32,387	-42,427
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]	'	'
Balance - beginning	262,683	-12,432
Other comprehensive income before reclassifications	-380,487	685,476
Net current period other comprehensive income	-380,487	685,476
Balance - end	($117,804)	$673,044